Sulfolobus phosphotriesterase-like (PLL) lactonase activity with enhanced properties and uses thereof

By introducing mutations at the active site of thiocetetrasterase-like lactonease (PLL), a highly active extreme thermophilic PTE was developed, which solved the problems of OP poisoning treatment and pollution removal, and achieved efficient and economical OP and AHL hydrolysis and pollution removal enhance the ability to respond to OP pollution.

CN105209061BActive Publication Date: 2024-11-26CENT NAT DE LA RECH SCI (C N R S) +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201480027328.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2013-04-12
Filing Date
2014-04-14
Publication Date
2024-11-26
Estimated Expiration
2034-04-14

AI Technical Summary

Technical Problem

The existing treatment methods for organophosphate (OP) poisoning are not effective enough, and the use of OP hydrolase requires a large number of enzymes, which leads to high costs. The chemical warfare agents formed after the toxicity and stability of OP are increased pose a serious threat to the human body. Antidotes and protections are not enough to deal with this crisis.

Method used

Developing enhanced activity of thiocetetriesterase-like lactonease (PLL), by introducing mutations at its active site, improves activity against organophosphate (OP) and anti-ribe quencher (AHL) and New compositions are formed by mutated extreme thermophilic PTE for decontamination and bioscavengers for OP contamination.

Benefits of technology

It achieves efficient hydrolysis of OP and AHL, improves the effect of OP poisoning treatment, reduces treatment costs, and provides effective decontamination and biological removal of OP contamination, enhancing the ability to destroy neurotoxic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0000845817790001311
    Figure BDA0000845817790001311
  • Figure BDA0000845817790001321
    Figure BDA0000845817790001321
  • Figure BDA0000845817790001322
    Figure BDA0000845817790001322
Patent Text Reader

Abstract

This invention provides a mutant extreme thermophilic PTE with lactonease activity, derived from an extreme thermophilic phosphodiesterase corresponding to the common sequence of SEQ ID NO:1. The mutant PTE comprises at least one mutation selected from 53 presumed positions, and the mutant PTE exhibits enhanced properties. Furthermore, this invention provides compositions comprising the mutant extreme thermophilic PTE and their uses, particularly as bioscavengers of organophosphate compounds or as quorum quenchers for bacteria communicating using lactones.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to Sulfolobal Phosphotriesterase-Like Lactonase (PLL) activity with enhanced properties and its use, in particular as a bioscavenger of organophosphorus compounds or as a quorum quencher of bacteria that use lactones for communication.

[0002] Organophosphate (OP) insecticides have become the most widely used insecticides currently available. OPs are used in agriculture, in homes, in parks, and in veterinary practice. Since most of these compounds inhibit certain esterases, exposure to OPs can lead to severe toxicity through multiple pathways. OPs irreversibly inhibit acetylcholinesterase, an important enzyme of the mammalian nervous system, causing severe damage in all vertebrates. Loss of enzyme function leads to accumulation of acetylcholine in different compartments of the body, resulting in muscle contraction, paralysis, and respiratory depression. Increased pulmonary secretion with respiratory failure is a common cause of death from organophosphate poisoning.

[0003] Prior to World War II, some OPs were also developed by the military. The discovery of OPs with improved toxicity and / or increased stability led to the development of chemical warfare agents (CWAs), such as sarin, soman, tabun, or VX. In addition, OP insecticides (which are more readily available than CWA OPs, but are not as toxic) posed a significant risk to the population. Faced with these increased threats, the development of antidotes became more urgent.

[0004] Due to the hydrophobicity of OP, it is efficiently absorbed by inhalation, digestion and skin penetration. The occurrence of poisoning depends on the absorption rate of the compound. Depending on the method of contact, symptoms of acute OP poisoning develop within minutes to hours during or after exposure. Exposure by absorption leads to the fastest onset of toxic symptoms, followed by the gastrointestinal route and finally the dermal route.

[0005] Protective garments and masks do not always provide effective protection against OP. In patients poisoned by OP contamination of the skin, clothing or hair, surgical soap or laundry detergent must be used for the decontamination process. Treatment of highly contaminated people requires the administration of atropine or diazepam, which antagonize the effects of excessive concentrations of acetylcholine in end organs with muscarinic receptors. Unfortunately, atropine is ineffective against nicotinic acid effects, which in severe poisoning are specifically muscle weakness and respiratory depression. When pralidoxime (a cholinesterase activator) is administered less than 48 hours after poisoning, it reduces the nicotinic acid and muscarinic effects of OP poisoning. The use of such compounds is ineffective against sarin (which maintains an extremely rapid effect once inhaled). In addition, clearing the airways and improving tissue oxygenation are also very helpful.

[0006] Although the above-mentioned technologies have resulted in some progress in prevention, existing protection and treatment of these poisonings remain unsatisfactory.

[0007] In the early 1990s, the first OP hydrolases were identified in several bacteria (Cheng et al., 1993, Appl. Environ. Microbiol., 59: 3138-3140, Raveh et al., 1993, Biochem Pharmacol., 45: 2465-2474). These enzymes are able to catalyze the hydrolysis of phosphoester bonds in OPs. Unfortunately, due to their low stoichiometric binding capacity with OPs, huge amounts of enzymes are required to cure poisoned individuals. This results in disproportionate and very expensive use of these enzymes.

[0008] Some other microbial enzymes, collectively known as phosphotriesterases (PTEs), show a preference for organophosphorus compounds with PO or PS bonds. These enzymes are members of the aminohydrolase superfamily, enzymes that catalyze the hydrolysis of a wide range of compounds (phospholipids, esters, amides, etc.) with different chemical properties. Their encoding gene opd (organophosphate degradation gene) was isolated in soil bacteria, such as Pseudomonas diminuta, also known as Brevundominas diminuta (Munnecke et al., 1976, Appl. Environ. Microbiol., 32: 7-13); species of Falvobacterium (Sethunathan et al., 1973, Can J Microbiol, 19: 873-875); and Agrobacterium radiobacter (Horne et al., 2003, FEMS Microbiol Lett, 222: 1-8), and genes similar to opd have also been identified in archaea (Merone et al., 2005, Extremophiles, 9: 297-305). Since extreme thermophilic PTE can hydrolyze pesticides and various neurotoxic agents, the catalytic properties of extreme thermophilic PTE have been widely studied (Jackson et al., 2005, Biochem Biophys Acta, 1752: 56-64 / Jackson et al., 2008, J Mol Biol, 375: 1189-1196 / Wong et al., 2007, Biochemistry, 46: 13352-13369 / Elias et al., 2008, J Mol Biol, 379: 1017-1028 / Pompea et al., 2009, Extremophiles, 13: 461-470). Since extreme thermophilic PTE has the ability to resist organic solvents or detergents at moderate temperatures, it has the advantages of being very stable and inexpensive to produce. Therefore, extreme thermophilic PTE is expected to be used in the development of bioremoval agents for neurotoxic agents (OP).

[0009] Recently, three extremely thermophilic PTEs were isolated and purified from Sulfolobus sp.: SsoPox from Sulfolobus solfataricus (Merone et al., 2005, Extremophiles, 9:297-305); SacPox from Sulfolobus acidicaldarius (Porzio et al., 2007, Biochimie, 89:625-636); and SisLac (also known as SisPox) from Sulfolobus islandicus (Gotthard et al., 2011, Acta Crystallogr Sect F Struct Biol Cryst Commun 67:354-357 / Hiblot et al., 2012, PLoS One 7:e47028). SsoPox, SacPox and SisLac are members of an enzyme family known as phosphotriesterase-like lactonase (PLL). Phylogenetic and biochemical studies have shown that SsoPox and SisLac enzymes are natural lactonase enzymes endowed with promiscuous paraoxonase activity, and more generally, have organophosphate hydrolase activity (Afriat et al., 2006, Biochemistry, 45: 13677-13686 / Elias et al., 2012, J Biol Chem., 287 (1): 11-20). Although PTE and PLL enzymes exhibit the same (β / α) 8-barrel fold or so-called TIM barrel, their ability to hydrolyze different substrates (e.g., lactones or OPs) is different.

[0010] Lactones are signaling molecules synthesized by bacteria, allowing them to be used to detect the density of a population. This process of cell-to-cell communication is called quorum sensing (QS) and is known to regulate many key biological functions of bacteria, including biofilm formation (Popat et al., 2008, British Medical Bulletin, 87: 63-75). The connection between QS and virulence is central to the pathogenesis of many bacterial infections, including P. aeruginosa (Sakuragi et al., 2007, J Bacteriol, 189:5383-5386), but also Acinetobacter baumanii (Stacy et al., 2012, ACS Chem Biol, 7(10):1719-1728), Burkholderia sp. (McKeon et al., 2011, J Infect Dis, Feb 1;203(3):383-92), Vibrio species (Augustine et al., 2010, Arch Microbiol 192(12):1019-1022) or E. caratovora (Dong et al., 2013, ACS Chem Biol, 7(10):1719-1728). al., 2001, Nature, 411: 813-817). Interference with QS systems (also known as quorum quenching) is a promising approach to control bacterial diseases in plants and animals (Dong et al., 2001, Nature, 411: 813-817). N-acyl homoserine lactones (AHLs) are molecules that mediate bacterial communication in many Gram-negative bacteria and some archaeal organisms (Zhang et al., 2012, ISME J., Jul; 6(7): 1336-44). They traditionally regulate infection and virulence. These molecules accumulate in the medium, reaching a certain threshold that can change the bacterial transcriptional profile (Hentzer et al., 2003, Embo J, 22: 3803-3815). By hydrolyzing AHLs, lactonase-like PLL can quench AHL-mediated communication between bacteria, as seen in human paraoxonase (Ma et al., 2009, Appl Microbiol Biotechnol, 83: 135-141) or AiiA lactonase (Dong et al., 2001, Nature, 411: 813-817). Due to its dual catalytic activity (lactonase and phosphotriesterase), PLL constitutes a highly attractive candidate for biotechnological applications as a quorum quencher or OP bioscavenger.

[0011] In WO 2008 / 145865, the inventors of the present invention provided a novel PTE with higher activity against OP by introducing mutations in the active site next to SsoPox. The main aim of this work was to obtain a novel enzyme with catalytic properties close to a mesophilic PTE.

[0012] Surprisingly, the present inventors have found that introducing mutations in various beta sheets or loops of the PLL enzyme not only increases the OP hydrolysis activity, but also increases the lactonase activity of the enzyme.

[0013] One aspect of the present invention provides a novel mutant extremely thermophilic PTE having lactonase activity, which has the following two advantages:

[0014] - higher activity against OPs, or higher activity against AHLs, or higher activity against OPs and against AHLs than the wild-type extremely thermophilic PTE;

[0015] -More stable and cheaper to produce than mesophilic PTE.

[0016] Another aspect of the present invention contemplates methods for creating libraries of mutant hyperthermophilic PTE variants.

[0017] Another aspect of the present invention provides an effective tool for decontaminating the surface of materials, skin, hair or mucous membranes contaminated by OP. The tool can be a composition, a biological remover, a decontamination box, a decontamination kit, or an impregnation material having a new mutant extremely thermophilic PTE.

[0018] Another aspect of the present invention provides vectors and host cells that enable large-scale synthesis of new mutant hyperthermophilic PTEs at reduced cost.

[0019] Another aspect of the invention relates to the use of novel mutated extremely thermophilic PTEs as bioscavengers in the context of decontamination of surfaces of materials, skin or mucous membranes contaminated with organophosphorus compounds, or in the context of pollution control of water contaminated with organophosphorus compounds, or in the context of destroying a large number of neurotoxic agents.

[0020] Another aspect of the present invention provides a composition comprising a novel mutated extremely thermophilic PTE for use in treating diseases caused by bacteria that use AHLs for communication. The expression bacteria not only involves bacteria, but also archaea.

[0021] The subject of the present invention is a mutant hyperthermophilic PTE having lactonase activity, the mutant hyperthermophilic PTE being derived from a hyperthermophilic phosphotriesterase corresponding to the consensus sequence of SEQ ID NO: 1, the mutant PTE comprising at least one mutation selected from the group consisting of: except for positions 48, 132, 166, 267, 269, 272, 279, 282, 283 and 299, SEQ ID In NO:1, glycine G at position 9, lysine K at position 10, valine V at position 29, phenylalanine F or leucine L at position 48, lysine K at position 56, proline P at position 69, threonine T at position 70, leucine L at position 74, isoleucine I at position 78, valine V at position 85, tyrosine Y at position 99, tyrosine Y at position 101, isoleucine I at position 124, leucine L or serine S or asparagine N at position 132, aspartic acid D at position 143, Lysine K or asparagine N, Isoleucine I at position 169, Aspartic acid D at position 193, Glycine G at position 195, Arginine R at position 225, Glycine G at position 227, Leucine L at position 228, Leucine L at position 230, Phenylalanine F at position 231, Leucine L at position 232, Tyrosine Y at position 259, Cysteine ​​C at position 260, Cysteine ​​C at position 261, Threonine T at position 262, Isoleucine I at position 263, Aspartic acid D at position 264, tryptophan W at position 65, glycine G at position 266, threonine T or isoleucine I at position 267, alanine A at position 268, lysine K or arginine R at position 269, proline P at position 270, glutamic acid E at position 271, tyrosine Y or leucine L at position 272, lysine K at position 273, proline P at position 274, lysine K at position 275, leucine L at position 276, alanine A at position 277, proline P at position 278, arginine R or lysine K at position 279, the tryptophan W at position 80, the serine S at position 281, the isoleucine I or methionine M at position 282, the threonine T or alanine A or serine S at position 283, the leucine L at position 284, the isoleucine I at position 285, the asparagine N or serine S or threonine T at position 299 are substituted by any other natural amino acid different from the amino acid described in the consensus sequence, wherein said substitution can be performed using one of the amino acids described in the consensus sequence, as long as said substitution at said position is always associated with at least one other substitution selected from the above positions;or by any other unnatural amino acid, provided that when at least one mutation is selected from the group consisting of substitution with tyrosine Y at position 99, tyrosine Y at position 101, arginine R at position 225, cysteine ​​C at position 260, said at least one mutation is always associated with at least one mutation selected from the group consisting of substitution with glycine G at position 9, lysine K at position 10, phenylalanine F or leucine L at position 48, lysine K at position 56, isoleucine I at position 78, valine V at position 85, isoleucine I at position 124, leucine L or serine S or asparagine N at position 132, lysine K or asparagine N at position 166, isoleucine I at position 169, aspartic acid D at position 193, glycine G at position 195, leucine L at position 230, leucine L at position 232, tyrosine Y at position 259, cysteine ​​C at position 261, Threonine T at position 262, isoleucine I at position 263, aspartic acid D at position 264, glycine G at position 266, threonine T or isoleucine I at position 267, alanine A at position 268, lysine K or arginine R at position 269, proline P at position 270, glutamic acid E at position 271, tyrosine Y or leucine L at position 272, lysine K at position 273, proline P at position 274, lysine K at position 275, leucine L at position 276, alanine A at position 277, proline P at position 278, arginine R or lysine K at position 279, serine S at position 281, isoleucine I or methionine M at position 282, threonine T or alanine A or serine S at position 283, leucine L at position 284, isoleucine I at position 285, asparagine N or serine S or threonine T at position 299;The prerequisite is that at least one mutation selected from the group consisting of valine V at position 29, proline P at position 69, threonine T at position 70, leucine L at position 74, aspartic acid D at position 143, glycine G at position 227, leucine L at position 228, phenylalanine F at position 231, tryptophan W at position 265, and tryptophan W at position 280 and at least one mutation selected from the group consisting of tyrosine Y at position 99, tyrosine Y at position 101, arginine R at position 225, and cysteine ​​C at position 260 are replaced. When the mutations are associated to form associated mutations, the associated mutations are always associated with at least one mutation selected from the following substitutions: glycine G at position 9, lysine K at position 10, phenylalanine F or leucine L at position 48, lysine K at position 56, isoleucine I at position 78, valine V at position 85, isoleucine I at position 124, leucine L or serine S or asparagine N at position 132, lysine K or asparagine N at position 166, isoleucine I at position 169, asparagine at position 193 Acid D at position 195, glycine G at position 230, leucine L at position 232, tyrosine Y at position 259, cysteine ​​C at position 261, threonine T at position 262, isoleucine I at position 263, aspartic acid D at position 264, glycine G at position 266, threonine T or isoleucine I at position 267, alanine A at position 268, lysine K or arginine R at position 269, proline P at position 270, glutamic acid E at position 271, tyrosine at position 272 Y or leucine L, lysine K at position 273, proline P at position 274, lysine K at position 275, leucine L at position 276, alanine A at position 277, proline P at position 278, arginine R or lysine K at position 279, serine S at position 281, isoleucine I or methionine M at position 282, threonine T or alanine A or serine S at position 283, leucine L at position 284, isoleucine I at position 285, asparagine N or serine S or threonine T at position 299.;

[0022] PTEs are zinc-metalloproteases that were originally identified as being able to hydrolyze organophosphorus compounds containing phosphotriesterases, but more recently more members of this family have been found to also possess lactonase activity. Lactonase activity is able to hydrolyze esters bound in the lactone ring.

[0023] The expression "mutated hyperthermophilic PTE with lactonase activity" relates to any enzyme having lactonase and phosphotriesterase catalytic activity, which is isolated from thermophilic or hyperthermophilic bacteria belonging to the PLL or PTE superfamily. "Superfamily" refers to a large class of proteins that share the same fold (topological structure and secondary structure elements) and the same active site structure. The superfamily consists of several large classes of proteins that share the same three-dimensional structure and function, each class exhibiting different functions. These functions usually share common elements (such as important chemical steps in enzyme catalysis) and also have residues that form the active site of the element. "Thermophilic bacteria" refers to bacteria that live between 45°C and 120°C. "Extreme thermophilic bacteria" refers to bacteria whose optimal temperature is above 80°C. The thermal stability of enzymes isolated from thermophilic or hyperthermophilic bacteria gives them the advantage of cheap production, on the one hand because they are stable in organic solvents (which makes them more suitable for industrial processes), and on the other hand because they can be purified extremely cheaply by the technique of heating cell lysates of cells (producing the above enzymes), thus obtaining high yields and high purity in one stage.

[0024] According to the methods disclosed in the experimental part of the present invention, the catalytic activities of lactonase and phosphotriesterase can be tested on their respective substrates.

[0025] It is noteworthy that, due to the selection of restriction endonucleases in the cloning site of the vector used to construct the mutant hyperthermophilic PTE, the amino acid residues were introduced at position 2 of SEQ ID NO: 1 by the experimental protocol for forming different mutant hyperthermophilic PTEs. For example, the use of NcoI restriction endonuclease in the cloning site of the vector resulted in the addition of an alanine residue at position 2 of SEQ ID NO: 1 to avoid a change in the reading frame. The introduction of the alanine residue at position 2 of SEQ ID NO: 1 had no effect on the activity of the wild-type or mutant hyperthermophilic PTE. This means that two mutant hyperthermophilic PTEs having a sequence derived from SEQ ID NO: 1, one of which had an alanine residue added at position 2 and the other of which did not contain the alanine residue at position 2, had exactly the same enzymatic activity in terms of performance.

[0026] For positions 48, 132, 166, 267, 269, 272, 279, 282, 283 and 299, one of the amino acids described in the consensus sequence can be substituted, i.e. an amino acid already present in the natural hyperthermophilic PTE, as long as the substitution at the position is always associated with at least one other substitution selected in the above positions. For example, if the phenylalanine F at position 48 is replaced by a leucine L, another substitution should be made at least in any of the 52 other positions disclosed.

[0027] The first clause is intended to exclude single mutations at positions Y99, Y101, R225 or C260 of SEQ ID NO:1. When the native amino acid at one of the above positions is mutated, it is always associated with at least one of the 39 substitutions at positions G9, K10, F / L48, K56, I78, V85, 1124, L / S / N132, K / N166, 1169, D193, G195, L230, L232, Y259, C261, T262, 1263, D264, G266, T / I267, A268, K / R269, P270, E271, Y / L272, K273, P274, K275, L276, A277, P278, R / K279, S281, I / M282, T / A / S283, L284, 1285, N / S / T299 of SEQ ID NO:1.

[0028] The purpose of the second clause is to exclude all combinations of at least one mutation selected from the following: a substitution of valine V at position 29, a substitution of proline P at position 69, a substitution of threonine T at position 70, a substitution of leucine L at position 74, a substitution of aspartic acid D at position 143, a substitution of glycine G at position 227, a substitution of leucine L at position 228, a substitution of phenylalanine F at position 231, a substitution of tryptophan W at position 265, and a substitution of tryptophan W at position 280 associated with at least one mutation selected from SEQ IDNO:1. When a combination of such mutations occurs, it is always associated with at least one of the 39 substitutions at positions G9, K10, F / L48, K56, I78, V85, 1124, L / S / N132, K / N166, 1169, D193, G195, L230, L232, Y259, C261, T262, 1263, D264, G266, T / I267, A268, K / R269, P270, E271, Y / L272, K273, P274, K275, L276, A277, P278, R / K279, S281, I / M282, T / A / S283, L284, 1285, N / S / T299 of SEQ ID NO:1.

[0029] The above clause is intended to exclude some specific mutant extremely thermophilic phosphotriesterases (PTEs) previously disclosed by the present inventors in WO 2008 / 145865.

[0030] The mutant extremely thermophilic phosphotriesterase (PTE) with lactonase activity of the present invention has the advantage of higher activity than the wild-type extremely thermophilic phosphotriesterase (PTE) with lactonase activity from which it is derived, not only in the context of hydrolyzing OP, but also in the context of treating diseases caused by bacteria that use AHL for communication (notably, hydrolyzing AHL).

[0031] In addition, the extremely thermophilic PTE having lactonase activity of the present invention has the advantage of having higher activity than the wild-type extremely thermophilic PTE from which it is derived under the following backgrounds:

[0032] - in the context of hydrolysis of OP, and / or

[0033] - in the context of quorum quenching, i.e., in the context of protection against pathogen infection.

[0034] In a preferred embodiment, the mutant extremely thermophilic phosphotriesterase (PTE) has lactonase activity and is derived from an extremely thermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and the mutant PTE comprises at least one mutation selected from the group consisting of: except for positions 47, 131, 165, 266, 268, 271, 278, 281, 282 and 298, In NO:1, glycine G at position 8, lysine K at position 9, valine V at position 28, phenylalanine F or leucine L at position 47, lysine K at position 55, proline P at position 68, threonine T at position 69, leucine L at position 73, isoleucine I at position 77, valine V at position 84, tyrosine Y at position 98, tyrosine Y at position 100, isoleucine I at position 123, leucine L or serine S or asparagine N at position 131, aspartic acid D at position 142, Lysine K or asparagine N, Isoleucine I at position 168, Aspartic acid D at position 192, Glycine G at position 194, Arginine R at position 224, Glycine G at position 226, Leucine L at position 227, Leucine L at position 229, Phenylalanine F at position 230, Leucine L at position 231, Tyrosine Y at position 258, Cysteine ​​C at position 259, Cysteine ​​C at position 260, Threonine T at position 261, Isoleucine I at position 262, Aspartic acid D at position 263, tryptophan W at position 64, glycine G at position 265, threonine T or isoleucine I at position 266, alanine A at position 267, lysine K or arginine R at position 268, proline P at position 269, glutamic acid E at position 270, tyrosine Y or leucine L at position 271, lysine K at position 272, proline P at position 273, lysine K at position 274, leucine L at position 275, alanine A at position 276, proline P at position 277, arginine R or lysine K at position 278, the tryptophan W at position 79, the serine S at position 280, the isoleucine I or methionine M at position 281, the threonine T or alanine A or serine S at position 282, the leucine L at position 283, the isoleucine I at position 284, the asparagine N or serine S or threonine T at position 298 are substituted by any other natural amino acid different from the amino acid described in the consensus sequence, wherein said substitution can be performed with one of the amino acids described in the consensus sequence, as long as said substitution at said position is always associated with at least one other substitution selected from the above positions;or by any other unnatural amino acid, provided that when at least one mutation is selected from the group consisting of substitution with tyrosine Y at position 98, tyrosine Y at position 100, arginine R at position 224, cysteine ​​C at position 259, said at least one mutation is always associated with at least one mutation selected from the group consisting of substitution with glycine G at position 8, lysine K at position 9, phenylalanine F or leucine L at position 47, lysine K at position 55, isoleucine I at position 77, valine V at position 84, isoleucine I at position 123, leucine L or serine S or asparagine N at position 131, lysine K or asparagine N at position 165, isoleucine I at position 168, aspartic acid D at position 192, glycine G at position 194, leucine L at position 229, leucine L at position 231, tyrosine Y at position 258, cysteine ​​C at position 260, 261 threonine T, 262 isoleucine I, 263 aspartic acid D, 265 glycine G, 266 threonine T or isoleucine I, 267 alanine A, 268 lysine K or arginine R, 269 proline P, 270 glutamic acid E, 271 tyrosine Y or leucine L, 272 lysine K, 273 proline P, 274 lysine K, 275 arginine R, 276 tyrosine Y or leucine L, 277 lysine K, 278 proline P, 279 glutamic acid E, 280 tyrosine Y or leucine L, 281 tyrosine Y or leucine L, 282 lysine K, 283 proline P, 284 lysine K, 285 lysine K at position 274, leucine L at position 275, alanine A at position 276, proline P at position 277, arginine R or lysine K at position 278, serine S at position 280, isoleucine I or methionine M at position 281, threonine T or alanine A or serine S at position 282, leucine L at position 283, isoleucine I at position 284, asparagine N or serine S or threonine T at position 298;The prerequisite is that at least one mutation selected from the group consisting of valine V at position 28, proline P at position 68, threonine T at position 69, leucine L at position 73, aspartic acid D at position 142, glycine G at position 226, leucine L at position 227, phenylalanine F at position 230, tryptophan W at position 264, and tryptophan W at position 279 and at least one mutation selected from the group consisting of tyrosine Y at position 98, tyrosine Y at position 100, arginine R at position 224, and cysteine ​​C at position 259 are replaced. When a mutation is associated with a nucleotide sequence to form an associated mutation, the associated mutation is always associated with at least one mutation selected from the following: glycine G at position 8, lysine K at position 9, phenylalanine F or leucine L at position 47, lysine K at position 55, isoleucine I at position 77, valine V at position 84, isoleucine I at position 123, leucine L or serine S or asparagine N at position 131, lysine K or asparagine N at position 165, isoleucine I at position 168, aspartic acid D at position 192 , glycine G at position 194, leucine L at position 229, leucine L at position 231, tyrosine Y at position 258, cysteine ​​C at position 260, threonine T at position 261, isoleucine I at position 262, aspartic acid D at position 263, glycine G at position 265, threonine T or isoleucine I at position 266, alanine A at position 267, lysine K or arginine R at position 268, proline P at position 269, glutamic acid E at position 270, tyrosine Y at position 271 or leucine L, lysine K at position 272, proline P at position 273, lysine K at position 274, leucine L at position 275, alanine A at position 276, proline P at position 277, arginine R or lysine K at position 278, serine S at position 280, isoleucine I or methionine M at position 281, threonine T or alanine A or serine S at position 282, leucine L at position 283, isoleucine I at position 284, asparagine N or serine S or threonine T at position 298.;

[0035] In this preferred embodiment, the alanine residue at position 2 is absent in SEQ ID NO:1.

[0036] The first clause is intended to exclude single mutations at positions Y98, Y100, R224 or C259 of SEQ ID NO:1. When the native amino acid at one of the above positions is mutated, it is always associated with at least one of the 39 substitutions at positions G8, K9, F / L47, K55, I77, V84, 1123, L / S / N131, K / N165, 1168, D192, G194, L229, L231, Y258, C260, T261, 1262, D263, G265, T / I266, A267, K / R268, P269, E270, Y / L271, K272, P273, K274, L275, A276, P277, R / K278, S280, I / M281, T / A / S282, L283, 1284, N / S / T298 of SEQ ID NO:1.

[0037] The purpose of the second clause is to exclude all combinations of at least one of the following mutations: a substitution of valine V at position 28, a substitution of proline P at position 68, a substitution of threonine T at position 69, a substitution of leucine L at position 73, a substitution of aspartic acid D at position 142, a substitution of glycine G at position 226, a substitution of leucine L at position 227, a substitution of phenylalanine F at position 230, a substitution of tryptophan W at position 264, and a substitution of tryptophan W at position 279 associated with at least one mutation selected from SEQ ID NO:1. When a combination of such mutations occurs, it is always associated with at least one of the 39 substitutions at positions G8, K9, F / L47, K55, I77, V84, I123, L / S / N131, K / N165, I168, D192, G194, L229, L231, Y258, C260, T261, I262, D263, G265, T / I266, A267, K / R268, P269, E270, Y / L271, K272, P273, K274, L275, A276, P277, R / K278, S280, I / M281, T / A / S282, L283, I284, N / S / T298 of SEQ ID NO:1.

[0038] In a more preferred embodiment, the mutated extremely thermophilic PTE having lactonase activity according to the present invention corresponds to the sequence of SEQ ID NO:3 or has at least 70% or higher identity with the amino acid sequence of SEQ ID NO:3, wherein the mutated PTE comprises at least one mutation selected from the group consisting of: glycine G at position 7, lysine K at position 8, valine V at position 27, phenylalanine F at position 46, lysine K at position 54, proline P at position 67, threonine T at position 68, leucine L at position 72, isoleucine I at position 76, valine V at position 83, tyrosine Y at position 97, tyrosine Y at position 99, isoleucine I at position 122, leucine L at position 130, aspartic acid D at position 141, threonine T at position 68, leucine L at position 72, isoleucine I at position 76, valine V at position 83, tyrosine Y at position 97, tyrosine Y at position 99, isoleucine I at position 122, leucine L at position 130, aspartic acid D at position 141, lysine K at position 167, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, arginine R at position 223, glycine G at position 225, leucine L at position 226, leucine L at position 228, phenylalanine F at position 229, leucine L at position 230, tyrosine Y at position 257, cysteine ​​C at position 258, cysteine ​​C at position 259, threonine T at position 260, isoleucine I at position 261, Aspartic acid D at position 262, tryptophan W at position 263, glycine G at position 264, threonine T at position 265, alanine A at position 266, lysine K at position 267, proline P at position 268, glutamic acid E at position 269, tyrosine Y at position 270, lysine K at position 271, proline P at position 272, lysine K at position 273, leucine L at position 274, alanine A at position 275, proline P at position 276, Arginine R at position 277, tryptophan W at position 278, serine S at position 279, isoleucine I at position 280, threonine T at position 281, leucine L at position 282, isoleucine I at position 283, asparagine N at position 297 are substituted with any other natural or unnatural amino acid, provided that when at least one mutation is selected from the group consisting of tyrosine Y at position 97, tyrosine Y at position 99, arginine R at position 223, cysteine ​​C at position 258,The at least one mutation is always associated with at least one mutation selected from the group consisting of: glycine G at position 7, lysine K at position 8, phenylalanine F at position 46, lysine K at position 54, isoleucine I at position 76, valine V at position 83, isoleucine I at position 122, leucine L at position 130, lysine K at position 164, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, leucine V at position 228 267, proline P at position 268, glutamic acid E at position 269, tyrosine Y at position 270, lysine K at position 271, aspartic acid D at position 272, glycine G at position 274, threonine T at position 275, alanine A at position 276, lysine K at position 277, proline P at position 278, glutamic acid E at position 279, tyrosine Y at position 280, lysine K at position 281, 272 proline P, 273 lysine K, 274 leucine L, 275 alanine A, 276 proline P, 277 arginine R, 279 serine S, 280 isoleucine I, 281 threonine T, 282 leucine L, 283 isoleucine I, 297 asparagine N; and provided that is selected from valine V at position 27, proline P at position 67, When at least one mutation of substitution of threonine T at position 68, leucine L at position 72, aspartic acid D at position 141, glycine G at position 225, leucine L at position 226, phenylalanine F at position 229, tryptophan W at position 263, and tryptophan W at position 278 is associated with at least one mutation selected from tyrosine Y at position 97, tyrosine Y at position 99, arginine R at position 223, and cysteine ​​C at position 258 to form a related mutation,Then the associated mutations are always associated with at least one mutation selected from the following substitutions: glycine G at position 7, lysine K at position 8, phenylalanine F at position 46, lysine K at position 54, isoleucine I at position 76, valine V at position 83, isoleucine I at position 122, leucine L at position 130, lysine K at position 164, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, leucine L at position 228, leucine L at position 230, tyrosine Y at position 257, cysteine ​​C at position 259, threonine T at position 260, isoleucine I at position 261, aspartic acid D at position 192, Aspartic acid D at position 264, glycine G at position 265, threonine T at position 266, alanine A at position 267, lysine K at position 268, proline P at position 269, glutamic acid E at position 269, tyrosine Y at position 270, lysine K at position 271, proline P at position 272, lysine K at position 273, leucine L at position 274, alanine A at position 275, proline P at position 276, arginine R at position 277, serine S at position 279, isoleucine I at position 280, threonine T at position 281, leucine L at position 282, isoleucine I at position 283, asparagine N at position 297. ,

[0039] In this more preferred embodiment, the alanine residue at position 2 and the threonine residue at position 3 are lacking in SEQ ID NO:1.

[0040] The first clause aims to exclude single mutations at positions Y97, Y99, R223 or C258 of SEQ ID NO:1. When the native amino acid at one of the above positions is mutated, it is always associated with at least one of the 39 substitutions at positions G7, K8, F46, K54, I76, V83, I122, L130, K164, I167, D191, G193, L228, L230, Y257, C259, T260, I261, D262, G264, T265, A266, K267, P268, E269, Y270, K271, P272, K273, L274, A275, P276, R277, S279, I280, T281, L282, I283, N297 of SEQ ID NO:1.

[0041] The purpose of the second clause is to exclude all combinations of at least one mutation selected from the following: substitution of valine V at position 27, substitution of proline P at position 67, substitution of threonine T at position 68, substitution of leucine L at position 72, substitution of aspartic acid D at position 141, substitution of glycine G at position 225, substitution of leucine L at position 226, substitution of phenylalanine F at position 229, substitution of tryptophan W at position 263, substitution of tryptophan W at position 278 associated with at least one mutation selected from SEQ IDNO:1. When a combination of such mutations occurs, it is always associated with at least one of the 39 substitutions at positions G7, K8, F46, K54, I76, V83, I122, L130, K164, I167, D191, G193, L228, L230, Y257, C259, T260, I261, D262, G264, T265, A266, K267, P268, E269, Y270, K271, P272, K273, L274, A275, P276, R277, S279, I280, T281, L282, I283, N297 of SEQ ID NO:1.

[0042] The present invention more specifically relates to the above-mentioned mutant extremely thermophilic PTE, which has lactonase activity and is derived from the extremely thermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO:1 is deleted, and the mutant PTE comprises at least one mutation selected from the following: in SEQ ID NO:1, valine V at position 28, proline P at position 68, threonine T at position 69, leucine L at position 73, tyrosine Y at position 98, tyrosine Y at position 100, aspartic acid D at position 142, arginine R at position 224, glycine G at position 226, leucine L at position 227, phenylalanine F at position 230, cysteine ​​C at position 259, tryptophan W at position 264, and tryptophan W at position 279 are substituted by any other natural amino acid different from the amino acid described in the consensus sequence or by any other non-natural amino acid.

[0043] In an even more specific embodiment, the above-mentioned mutant extremely thermophilic PTE has lactonase activity and is derived from an extremely thermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO:1 is deleted, and the mutant PTE comprises only one mutation, which is selected from: in SEQ ID NO:1, valine V at position 28, proline P at position 68, threonine T at position 69, leucine L at position 73, aspartic acid D at position 142, glycine G at position 226, leucine L at position 227, phenylalanine F at position 230, tryptophan W at position 264, and tryptophan W at position 279 are substituted by any other natural amino acid different from the amino acid described in the consensus sequence or by any other non-natural amino acid.

[0044] In a more specific embodiment, the above-mentioned mutant extremely thermophilic PTE has lactonase activity and is derived from an extremely thermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and the mutant PTE comprises at least one mutation selected from the group consisting of: SEQ ID NO: In NO:1, glycine G at position 8, lysine K at position 9, phenylalanine F or leucine L at position 47, lysine K at position 55, isoleucine I at position 77, valine V at position 84, isoleucine I at position 123, leucine L or serine S or asparagine N at position 131, lysine K or asparagine N at position 165, isoleucine I at position 168, aspartic acid D at position 192, glycine G at position 194, leucine L at position 229, leucine L at position 231, tyrosine Y at position 258, cysteine ​​C at position 260, threonine T at position 261, isoleucine I at position 262, aspartic acid D at position 263, glycine G at position 265, threonine T or isoleucine I at position 266, Alanine A, lysine K or arginine R at position 268, proline P at position 269, glutamate E at position 270, tyrosine Y or leucine L at position 271, lysine K at position 272, proline P at position 273, lysine K at position 274, leucine L at position 275, alanine A at position 276, proline P at position 277, arginine R or lysine K at position 278, serine S at position 280, isoleucine I or methionine M at position 281, threonine T at position 282 or alanine A or serine S, leucine L at position 283, isoleucine I at position 284, asparagine N or serine S or threonine T at position 298 are substituted with any other natural amino acid different from the amino acid described in the consensus sequence or with any other non-natural amino acid.

[0045] In a more specific embodiment, the above-mentioned mutant extremely thermophilic PTE has lactonase activity and is derived from an extremely thermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and the mutant PTE comprises only one mutation, and the mutation is selected from: SEQ ID NO: In NO:1, glycine G at position 8, lysine K at position 9, phenylalanine F or leucine L at position 47, lysine K at position 55, isoleucine I at position 77, valine V at position 84, isoleucine I at position 123, leucine L or serine S or asparagine N at position 131, lysine K or asparagine N at position 165, isoleucine I at position 168, aspartic acid D at position 192, glycine G at position 194, leucine L at position 229, leucine L at position 231, tyrosine Y at position 258, cysteine ​​C at position 260, threonine T at position 261, isoleucine I at position 262, aspartic acid D at position 263, glycine G at position 265, threonine T or isoleucine I at position 266, Alanine A, lysine K or arginine R at position 268, proline P at position 269, glutamate E at position 270, tyrosine Y or leucine L at position 271, lysine K at position 272, proline P at position 273, lysine K at position 274, leucine L at position 275, alanine A at position 276, proline P at position 277, arginine R or lysine K at position 278, serine S at position 280, isoleucine I or methionine M at position 281, threonine T at position 282 or alanine A or serine S, leucine L at position 283, isoleucine I at position 284, asparagine N or serine S or threonine T at position 298 are substituted with any other natural amino acid different from the amino acid described in the consensus sequence or with any other non-natural amino acid.

[0046] A more specific subject of the present invention is the above-mentioned mutant extremely thermophilic PTE with lactonase activity, which is derived from the extremely thermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO:3, or derived from the extremely thermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO:5, or derived from the extremely thermophilic PTE of Sulfolobus acidocaldarius corresponding to SEQ ID NO:7, wherein the sequences SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 belong to the consensus sequence SEQ ID NO:1, and the amino acid at position 2 in SEQ ID NO:1 is missing in SEQ ID NO:5, and the amino acids at positions 2 and 3 in SEQ ID NO:1 are missing in SEQ ID NO:3 and SEQ ID NO:7.

[0047] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, derived from the hyperthermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and wherein at least one mutation is selected from:

[0048] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0049] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0050] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0051] - the phenylalanine F at position 47 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L; or the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0052] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0053] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0054] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0055] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0056] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0057] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0058] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0059] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0060] - the leucine L or serine S or asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPIVADCT, in particular PT, especially P,

[0061] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0062] - the lysine K at position 165 is substituted by a polar amino acid selected from WYSTCNQRHDE, in particular NQR, especially N; or the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0063] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0064] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0065] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0066] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0067] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0068] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0069] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0070] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0071] - the tryptophan W at position 264 is substituted by a hydrophobic amino acid selected from VILMFGAPYC, or by a non-bulky amino acid selected from GPLIVADCSTN, in particular ALMFCITV, especially F, with the proviso that in SEQ ID NO: 3, the tryptophan W at position 264 is not substituted by a phenylalanine F,

[0072] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0073] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0074] - the isoleucine I or the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLFGAPWYC, in particular TYP, especially T,

[0075] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0076] - and the asparagine N or the serine S or the threonine T at position 298 is substituted by a polar amino acid selected from WYCQRKHDE, in particular Q.

[0077] These 29 specific substitutions at positions G8, K9, V28, F / L47, K55, T69, L73, I77, V84, Y98, Y100, I123, L / S / N131, D142, K / N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, I / M281, L283 and N / S / T298 belong to the first group of substitutions referred to as Group 1.

[0078] These positions are considered to be important positions for regulating enzyme activity and are also involved in the capacity of AHL substrates in the active site of the enzyme. The positions were identified by a directed evolution strategy.

[0079] The term "substitution" refers to the replacement of one amino acid by another. The substitution can be conservative, that is, the substituted amino acid is replaced by an amino acid of the same structure or with the same physicochemical properties (polar, hydrophobic, acidic, basic amino acids), so that the three-dimensional structure of the protein remains unchanged; or it is replaced by an opposite non-conservative amino acid.

[0080] When group 1 is related to a sequence, it means that in said sequence, at least one substitution of said group occurs.

[0081] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, derived from the hyperthermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and wherein at least one mutation is selected from:

[0082] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0083] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0084] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0085] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0086] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0087] - the aspartic acid D at position 263 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0088] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0089] - the Threonine T or Isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSN, in particular VWP, especially V,

[0090] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0091] - the lysine K or arginine R at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0092] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGACWY, in particular MCL, especially M,

[0093] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0094] - the tyrosine Y or the leucine L at position 271 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWC, in particular VA,

[0095] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0096] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0097] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular R,

[0098] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0099] - the arginine R or lysine K at position 278 is substituted by a bulky amino acid selected from WYSTCQNHDE, in particular DNQ, especially DN,

[0100] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0101] - the Threonine T or Alanine A or Serine S at position 282 is substituted by a non-bulky amino acid selected from GPLIVDCN or by a hydrophobic amino acid selected from VILMFGPWYC, in particular LV, especially L,

[0102] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0103] These 21 specific substitutions in positions I168, D192, Y258, C260, T261, D263, G265, T / I266, A267, K / R268, P269, E270, Y / L271, K272, P273, K274, P277, R / K278, S280, T / A / S282 and I 284 belong to a second group of substitutions referred to as Group 2.

[0104] These positions are primarily involved in the accommodation of AHL substrates in the active site of the enzyme. These positions were selected by analyzing the evolutionary history of the enzyme family.

[0105] When group 2 is related to a sequence, it means that in said sequence, at least one substitution of said group occurs.

[0106] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, derived from the hyperthermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and wherein at least one mutation is selected from:

[0107] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0108] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0109] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0110] These three specific substitutions in positions P68, G226 and W279 belong to a third group of substitutions referred to as Group 3.

[0111] These positions are highly suspected to be involved in the enzymatic activity of the enzyme.

[0112] When group 3 is related to a sequence, it means that in said sequence, at least one substitution of said group occurs.

[0113] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, derived from the hyperthermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and wherein at least one mutation is selected from:

[0114] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0115] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0116] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0117] - the phenylalanine F at position 47 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L; or the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0118] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0119] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0120] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0121] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0122] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0123] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0124] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0125] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0126] - the leucine L or serine S or asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPIVADCT, in particular PT, especially P,

[0127] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0128] - the lysine K at position 165 is substituted by a polar amino acid selected from WYSTCNQRHDE, in particular NQR, especially N, or the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0129] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0130] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0131] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0132] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0133] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0134] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0135] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0136] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0137] - the tryptophan W at position 264 is substituted by a hydrophobic amino acid selected from VILMFGAPYC, or by a non-bulky amino acid selected from GPLIVADCSTN, in particular ALMFCITV, especially F, with the proviso that in SEQ ID NO: 3, the tryptophan W at position 264 cannot be substituted by a phenylalanine F,

[0138] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0139] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0140] - the isoleucine I or the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLFGAPWYC, in particular TYP, especially T,

[0141] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0142] - and the asparagine N or the serine S or the threonine T at position 298 is substituted by a polar amino acid selected from the group consisting of WYCQRKHDE, in particular Q,

[0143] and further comprises at least one mutation selected from:

[0144] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0145] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0146] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0147] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0148] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0149] - the aspartic acid D at position 263 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0150] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0151] - the Threonine T or Isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSN, in particular VWP, especially V,

[0152] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0153] - the lysine K or arginine R at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0154] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGACWY, in particular MCL, especially M,

[0155] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0156] - the tyrosine Y or the leucine L at position 271 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWC, in particular VA,

[0157] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0158] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0159] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular R,

[0160] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0161] - the arginine R or lysine K at position 278 is substituted by a polar amino acid selected from WYSTCQNHDE, in particular DNQ, especially DN,

[0162] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0163] - the threonine T or the alanine A or the serine S at position 282 is substituted by a bulky amino acid selected from GPLIVDCN or by a hydrophobic amino acid selected from VILMFGPWYC, in particular LV, especially L,

[0164] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0165] This means that 29 of group 1 in positions G8, K9, V28, F / L47, K55, T69, L73, I77, V84, Y98, Y100, I123, L / S / N131, D142, N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, I / M281, L283, and N / S / T298 At least one of the specific substitutions can be associated with at least one of the 21 specific substitutions in Group 2 in positions I168, D192, Y258, C260, T261, D263, G265, T / I266, A267, K / R268, P269, E270, Y / L271, K272, P273, K274, P277, R / K278, S280, T / A / S282 and I284.

[0166] The present invention even more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, derived from the hyperthermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and wherein at least one mutation is selected from:

[0167] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0168] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0169] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0170] - the phenylalanine F at position 47 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L; or the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0171] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0172] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0173] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0174] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0175] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0176] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0177] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0178] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0179] - the leucine L or serine S or asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPIVADCT, in particular PT, especially P,

[0180] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0181] - the lysine K at position 165 is substituted by a polar amino acid selected from WYSTCNQRHDE, in particular NQR, especially N; or the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0182] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0183] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0184] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0185] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0186] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0187] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0188] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0189] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0190] - the tryptophan W at position 264 is substituted by a hydrophobic amino acid selected from VILMFGAPYC, or by a non-bulky amino acid selected from GPLIVADCSTN, in particular ALMFCITV, especially F, with the proviso that in SEQ ID NO: 3, the tryptophan W at position 264 cannot be substituted by a phenylalanine F,

[0191] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0192] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0193] - the isoleucine I or the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLFGAPWYC, in particular TYP, especially T,

[0194] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0195] - and the asparagine N or the serine S or the threonine T at position 298 is substituted by a polar amino acid selected from the group consisting of WYCQRKHDE, in particular Q,

[0196] Further comprising at least one mutation selected from:

[0197] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0198] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0199] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0200] This means that at least one of the 29 specific substitutions of group 1 in positions G8, K9, V28, F / L47, K55, T69, L73, I77, V84, Y98, Y100, I123, L / S / N131, D142, N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, I / M281, L283 and N / S / T298 can be associated with at least one of the 3 specific substitutions of group 3 in positions P68, G226 and W279.

[0201] The present invention even more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, derived from the hyperthermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and wherein at least one mutation is selected from:

[0202] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0203] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0204] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0205] - the phenylalanine F at position 47 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L; or the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0206] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0207] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0208] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0209] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0210] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0211] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0212] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0213] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0214] - the leucine L or serine S or asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPIVADCT, in particular PT, especially P,

[0215] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0216] - the lysine K at position 165 is substituted by a polar amino acid selected from WYSTCNQRHDE, in particular NQR, especially N; or the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0217] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0218] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0219] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0220] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0221] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0222] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0223] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0224] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0225] - the tryptophan W at position 264 is substituted by a hydrophobic amino acid selected from VILMFGAPYC, or by a non-bulky amino acid selected from GPLIVADCSTN, in particular ALMFCITV, especially F, with the proviso that in SEQ ID NO: 3, the tryptophan W at position 264 cannot be substituted by a phenylalanine F,

[0226] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0227] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0228] - the isoleucine I or the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLFGAPWYC, in particular TYP, especially T,

[0229] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0230] - and the asparagine N or the serine S or the threonine T at position 298 is substituted by a polar amino acid selected from the group consisting of WYCQRKHDE, in particular Q,

[0231] Further comprising at least one mutation selected from:

[0232] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0233] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0234] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0235] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0236] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0237] - the aspartic acid D at position 263 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0238] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0239] - the Threonine T or Isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSN, in particular VWP, especially V,

[0240] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0241] - the lysine K or arginine R at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0242] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGACWY, in particular MCL, especially M,

[0243] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0244] - the tyrosine Y or the leucine L at position 271 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWC, in particular VA,

[0245] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0246] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0247] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular R,

[0248] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0249] - the arginine R or lysine K at position 278 is substituted by a polar amino acid selected from WYSTCQNHDE, in particular DNQ, especially DN,

[0250] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0251] - the Threonine T or Alanine A or Serine S at position 282 is substituted by a non-bulky amino acid selected from GPLIVDCN or by a hydrophobic amino acid selected from VILMFGPWYC, in particular LV, especially L,

[0252] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[0253] Further comprising at least one mutation selected from the group consisting of:

[0254] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0255] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0256] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0257] This means that at least one of the 29 specific substitutions of Group 1 in positions G8, K9, V28, F / L47, K55, T69, L73, I77, V84, Y98, Y100, I123, L / S / N131, D142, N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, I / M281, L283, and N / S / T298 can be substituted. 68, D192, Y258, C260, T261, D263, G265, T / I266, A267, K / R268, P269, E270, Y / L271, K272, P273, K274, P277, R / K278, S280, T / A / S282 and I284 and is associated with at least one of the 3 specific substitutions in Group 3 in positions P68, G226 and W279.

[0258] The present invention even more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, derived from the hyperthermophilic phosphotriesterase according to the present invention, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted, and wherein at least one mutation is selected from:

[0259] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0260] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0261] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0262] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0263] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0264] - the aspartic acid D at position 263 is substituted by a non-bulky amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0265] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0266] - the Threonine T or Isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSN, in particular VWP, especially V,

[0267] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0268] - the lysine K or arginine R at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0269] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGACWY, in particular MCL, especially M,

[0270] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0271] - the tyrosine Y or the leucine L at position 271 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWC, in particular VA,

[0272] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0273] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0274] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular R,

[0275] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0276] - the arginine R or lysine K at position 278 is substituted by a polar amino acid selected from WYSTCQNHDE, in particular DNQ, especially DN,

[0277] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0278] - the Threonine T or Alanine A or Serine S at position 282 is substituted by a non-bulky amino acid selected from GPLIVDCN or by a hydrophobic amino acid selected from VILMFGPWYC, in particular LV, especially L,

[0279] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[0280] Further comprising at least one mutation selected from:

[0281] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0282] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0283] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0284] This means that at least one of the 21 specific substitutions of group 2 in positions I168, D192, Y258, C260, T261, D263, G265, T / I266, A267, K / R268, P269, E270, Y / L271, K272, P273, K274, P277, R / K278, S280, T / A / S282 and I284 can be associated with at least one of the 3 specific substitutions of group 3 in positions P68, G226 and W279.

[0285] The present invention even more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity and is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO:3, and the mutant PTE comprises at least one mutation selected from the following: in SEQ ID NO:3, valine V at position 27, proline P at position 67, threonine T at position 68, leucine L at position 72, tyrosine Y at position 97, tyrosine Y at position 99, aspartic acid D at position 141, arginine R at position 223, glycine G at position 225, leucine L at position 226, phenylalanine F at position 229, cysteine ​​C at position 258, tryptophan W at position 263 and tryptophan W at position 278 are substituted by any other natural or non-natural amino acids.

[0286] In an even more specific embodiment, the extremely thermophilic PTE having lactonase activity derived from the above-mentioned mutation of Sulfolobus solfataricus corresponding to the sequence of SEQ ID NO:3 comprises only one mutation selected from: in SEQ ID NO:3, valine V at position 27, proline P at position 67, threonine T at position 68, leucine L at position 72, aspartic acid D at position 141, glycine G at position 225, leucine L at position 226, phenylalanine F at position 229, tryptophan W at position 263 and tryptophan W at position 278 are substituted by any other natural or non-natural amino acid.

[0287] In a more specific embodiment, the above-mentioned mutant extremely thermophilic PTE has lactonase activity, is derived from the extremely thermophilic PTE of Sulfolobus solfataricus corresponding to the sequence of SEQ ID NO:3, and comprises at least one mutation selected from the following: in SEQ ID NO:3, glycine G at position 7, lysine K at position 8, phenylalanine F at position 46, lysine K at position 54, isoleucine I at position 76, valine V at position 83, isoleucine I at position 122, leucine L at position 130, lysine K at position 164, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, leucine L at position 228, leucine L at position 230, tyrosine Y at position 257, cysteine ​​C at position 259, threonine T at position 260, isoleucine I at position 261, aspartic acid D at position 262, glycine G at position 264, Threonine T at position 265, alanine A at position 266, lysine K at position 267, proline P at position 268, glutamic acid E at position 269, tyrosine Y at position 270, lysine K at position 271, proline P at position 272, lysine K at position 273, leucine L at position 274, alanine A at position 275, proline P at position 276, arginine R at position 277, serine S at position 279, isoleucine I at position 280, threonine T at position 281, leucine L at position 282, isoleucine I at position 283 and asparagine N at position 297 are substituted with any other natural or non-natural amino acids.

[0288] In an even more specific embodiment, the mutant hyperthermophilic PTE has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence of SEQ ID NO:3, and comprises only one mutation selected from the group consisting of: glycine G at position 7, lysine K at position 8, phenylalanine F at position 46, lysine K at position 54, isoleucine I at position 76, valine V at position 83, isoleucine I at position 122, leucine L at position 130, lysine K at position 164, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, leucine L at position 228, leucine L at position 230, tyrosine Y at position 257, cysteine ​​C at position 259, threonine T at position 260, isoleucine I at position 261, aspartic acid D at position 262, glycine G at position 264, Threonine T at position 265, alanine A at position 266, lysine K at position 267, proline P at position 268, glutamic acid E at position 269, tyrosine Y at position 270, lysine K at position 271, proline P at position 272, lysine K at position 273, leucine L at position 274, alanine A at position 275, proline P at position 276, arginine R at position 277, serine S at position 279, isoleucine I at position 280, threonine T at position 281, leucine L at position 282, isoleucine I at position 283 and asparagine N at position 297 are substituted with any other natural or non-natural amino acids.

[0289] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, and wherein at least one mutation is selected from:

[0290] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0291] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0292] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0293] - the phenylalanine F at position 46 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L,

[0294] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0295] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0296] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0297] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0298] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0299] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0300] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0301] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0302] - the leucine L at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0303] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0304] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0305] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0306] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0307] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0308] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0309] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0310] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0311] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0312] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0313] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMGAPYC, in particular ALMCITV,

[0314] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0315] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0316] - the isoleucine I at position 280 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TMYP, especially T,

[0317] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0318] - and the asparagine N at position 297 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QST, especially S.

[0319] These 29 specific substitutions in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, L130, D141, N164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, I280, L282 and N297 belong to a fourth group of substitutions referred to as Group 4.

[0320] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, and wherein at least one mutation is selected from:

[0321] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0322] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0323] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0324] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0325] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[0326] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[0327] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0328] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[0329] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0330] - the lysine K at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0331] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0332] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0333] - the tyrosine Y at position 270 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0334] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0335] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0336] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0337] - the proline P at position 276 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0338] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[0339] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0340] - the threonine T at position 281 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0341] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0342] These 21 specific substitutions in positions I167, D191, Y257, C259, T260, D262, G264, T265, A266, K267, P268, E269, Y270, K271, P272, K273, P276, R277, S279, T281 and I283 belong to the fifth group of substitutions referred to as Group 5.

[0343] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, and wherein at least one mutation is selected from:

[0344] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0345] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0346] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0347] These three specific substitutions in positions P67, G225 and W278 belong to the sixth group of substitutions in Group 6.

[0348] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, and wherein at least one mutation is selected from:

[0349] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0350] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0351] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0352] - the phenylalanine F at position 46 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L,

[0353] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0354] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0355] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0356] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0357] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0358] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0359] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0360] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0361] - the leucine L at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0362] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0363] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0364] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0365] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0366] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0367] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0368] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0369] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0370] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0371] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0372] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMGAPYC, in particular ALMCITV,

[0373] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0374] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0375] - the isoleucine I at position 280 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TMYP, especially T,

[0376] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0377] - and the asparagine N at position 297 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QST, especially S,

[0378] Further comprising at least one mutation selected from:

[0379] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0380] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0381] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0382] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0383] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[0384] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[0385] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0386] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[0387] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0388] - the lysine K at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0389] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0390] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0391] - the tyrosine Y at position 270 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0392] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0393] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0394] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0395] - the proline P at position 276 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0396] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[0397] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0398] - the threonine T at position 281 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0399] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0400] This means that 2 of group 4 in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, L130, D141, N164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, I280, L282 and N297 At least one of the 9 specific substitutions can be associated with at least one of the 21 specific substitutions in group 5 in positions I167, D191, Y257, C259, T260, D262, G264, T265, A266, K267, P268, E269, Y270, K271, P272, K273, P276, R277, S279, and T281.

[0401] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, and wherein at least one mutation is selected from:

[0402] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0403] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0404] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0405] - the phenylalanine F at position 46 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L,

[0406] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0407] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0408] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0409] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0410] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0411] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0412] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0413] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0414] - the leucine L at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0415] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0416] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0417] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0418] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0419] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0420] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0421] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0422] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0423] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0424] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0425] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMGAPYC, in particular ALMCITV,

[0426] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0427] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0428] - the isoleucine I at position 280 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TMYP, especially T,

[0429] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0430] - and the asparagine N at position 297 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QST, especially S,

[0431] Further comprising at least one mutation selected from:

[0432] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0433] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0434] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0435] This means that at least one of the 29 specific substitutions of group 4 in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, L130, D141, N164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, I280, L282 and N297 can be associated with at least one of the 3 specific substitutions of group 6 in positions P67, G225 and W278.

[0436] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, and wherein at least one mutation is selected from:

[0437] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0438] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0439] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0440] - the phenylalanine F at position 46 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular LYW, especially L,

[0441] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0442] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0443] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0444] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0445] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0446] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0447] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0448] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0449] - the leucine L at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0450] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0451] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0452] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0453] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0454] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0455] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0456] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0457] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0458] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0459] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0460] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMGAPYC, in particular ALMCITV,

[0461] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0462] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0463] - the isoleucine I at position 280 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TMYP, especially T,

[0464] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0465] - and the asparagine N at position 297 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QST, especially S,

[0466] Further comprising at least one mutation selected from:

[0467] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0468] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0469] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0470] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0471] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[0472] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[0473] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0474] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[0475] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0476] - the lysine K at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0477] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0478] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0479] - the tyrosine Y at position 270 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0480] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0481] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0482] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0483] - the proline P at position 276 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0484] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[0485] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0486] - the threonine T at position 281 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0487] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[0488] Further comprising at least one mutation selected from:

[0489] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0490] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0491] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0492] This means that at least one of the 29 specific substitutions of Group 4 in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, L130, D141, N164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, I280, L282 and N297 can be replaced with At least one of the 21 specific substitutions in group 5 in positions I167, D191, Y257, C259, T260, D262, G264, T265, A266, K267, P268, E269, Y270, K271, P272, K273, P276, R277, S279, T281, and at least one of the 3 specific substitutions in group 6 in positions P67, G225 and W278 are associated.

[0493] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, and wherein at least one mutation is selected from:

[0494] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0495] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0496] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0497] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0498] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[0499] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[0500] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0501] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[0502] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0503] - the lysine K at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0504] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0505] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0506] - the tyrosine Y at position 270 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0507] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0508] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0509] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0510] - the proline P at position 276 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0511] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[0512] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0513] - the threonine T at position 281 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0514] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[0515] Further comprising at least one mutation selected from:

[0516] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0517] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0518] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0519] This means that at least one of the 21 specific substitutions of group 5 in positions I167, D191, Y257, C259, T260, D262, G264, T265, A266, K267, P268, E269, Y270, K271, P272, K273, P276, R277, S279, T281 can be associated with at least one of the 3 specific substitutions of group 6 in positions P67, G225 and W278.

[0520] A more specific subject of the present invention is a mutant hyperthermophilic PTE having the lactonase activity according to the present invention, which is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO: 3, wherein the mutant hyperthermophilic PTE corresponds to the following sequence:

[0521] - SEQ ID NO: 9 corresponding to SEQ ID NO: 3 comprises one of the following mutations: tryptophan W at position 263 is replaced by methionine M,

[0522] - SEQ ID NO: 11 corresponding to SEQ ID NO: 3 comprises one of the following mutations: tryptophan W at position 263 is replaced by leucine L,

[0523] - SEQ ID NO: 13 corresponding to SEQ ID NO: 3 comprises one of the following mutations: tryptophan W at position 263 is replaced by alanine A,

[0524] - SEQ ID NO: 15 corresponding to SEQ ID NO: 3 comprises one of the following mutations: tryptophan W at position 263 is substituted by isoleucine I,

[0525] - SEQ ID NO: 17 corresponding to SEQ ID NO: 3 comprises one of the following mutations: tryptophan W at position 263 is replaced by valine V,

[0526] - SEQ ID NO: 19 corresponding to SEQ ID NO: 3 comprises one of the following mutations: tryptophan W at position 263 is replaced by threonine T,

[0527] - SEQ ID NO:21 corresponding to SEQ ID NO:3 comprises the following three mutations: cysteine ​​C at position 258 is substituted by leucine L, isoleucine I at position 261 is substituted by phenylalanine F, tryptophan W at position 263 is substituted by alanine A,

[0528] - SEQ ID NO:23 corresponding to SEQ ID NO:3 comprises the following 4 mutations: valine V at position 27 is substituted by alanine A, tyrosine Y at position 97 is substituted by tryptophan W, leucine L at position 228 is substituted by methionine M, tryptophan W at position 263 is substituted by methionine M,

[0529] - SEQ ID NO:25 corresponding to SEQ ID NO:3 comprises the following 4 mutations: valine V at position 27 is substituted by alanine A, tyrosine Y at position 97 is substituted by tryptophan W, tryptophan W at position 263 is substituted by leucine L, isoleucine I at position 280 is substituted by threonine T,

[0530] - SEQ ID NO:27 corresponding to SEQ ID NO:3 comprises the following 4 mutations: phenylalanine F at position 46 is substituted by leucine L, cysteine ​​C at position 258 is substituted by alanine A, tryptophan W at position 263 is substituted by methionine M, isoleucine I at position 280 is substituted by threonine T,

[0531] - SEQ ID NO:29 corresponding to SEQ ID NO:3 comprises the following 6 mutations: valine V at position 27 is substituted by alanine A, isoleucine I at position 76 is substituted by threonine T, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 130 is substituted by proline P, leucine L at position 226 is substituted by valine V,

[0532] - SEQ ID NO:31 corresponding to SEQ ID NO:3 comprises the following 6 mutations: leucine L at position 72 is substituted by isoleucine I, tyrosine Y at position 99 is substituted by phenylalanine F, isoleucine I at position 122 is substituted by leucine L, leucine L at position 228 is substituted by methionine M, phenylalanine F at position 229 is substituted by serine S, tryptophan W at position 263 is substituted by leucine L,

[0533] - SEQ ID NO:33 corresponding to SEQ ID NO:3 comprises the following 7 mutations: threonine T at position 68 is substituted by serine S, leucine L at position 72 is substituted by isoleucine I, leucine L at position 130 is substituted by proline P, leucine L at position 228 is substituted by methionine M, phenylalanine F at position 229 is substituted by serine S, tryptophan W at position 263 is substituted by methionine M, leucine L at position 274 is substituted by proline P,

[0534] - SEQ ID NO:35 corresponding to SEQ ID NO:3 comprises the following 6 mutations: threonine T at position 68 is substituted by serine S, isoleucine I at position 76 is substituted by threonine T, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 228 is substituted by methionine M, tryptophan W at position 263 is substituted by leucine L,

[0535] - SEQ ID NO:37 corresponding to SEQ ID NO:3 comprises the following 5 mutations: lysine K at position 8 is substituted by glutamic acid E, phenylalanine F at position 46 is substituted by leucine L, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 228 is substituted by methionine M,

[0536] - SEQ ID NO:39 corresponding to SEQ ID NO:3 comprises the following two mutations: leucine L at position 72 is substituted by isoleucine I, tryptophan W at position 263 is substituted by phenylalanine F,

[0537] - SEQ ID NO:41 corresponding to SEQ ID NO:3 comprises the following 5 mutations: threonine T at position 68 is substituted by serine S, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 130 is substituted by proline P, leucine L at position 228 is substituted by methionine M,

[0538] - SEQ ID NO:43 corresponding to SEQ ID NO:3 comprises the following 4 mutations: valine V at position 27 is substituted by alanine A, phenylalanine F at position 46 is substituted by leucine L, leucine L at position 226 is substituted by valine V, tryptophan W at position 263 is substituted by leucine L,

[0539] - SEQ ID NO:45 corresponding to SEQ ID NO:3 comprises the following 8 mutations: proline P at position 67 is substituted by valine V, threonine T at position 68 is substituted by serine S, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 228 is substituted by methionine M, cysteine ​​C at position 258 is substituted by alanine A, tryptophan W at position 263 is substituted by leucine L, isoleucine I at position 280 is substituted by threonine T,

[0540] - SEQ ID NO:47 corresponding to SEQ ID NO:3 comprises the following 8 mutations: phenylalanine F at position 46 is substituted by leucine L, threonine T at position 68 is substituted by serine S, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 130 is substituted by proline P, lysine K at position 164 is substituted by asparagine N, leucine L at position 226 is substituted by valine V, tryptophan W at position 263 is substituted by methionine M,

[0541] -SEQ ID NO:49 corresponding to SEQ ID NO:3 comprises the following 5 mutations: threonine T at position 68 is substituted by serine S, leucine L at position 72 is substituted by isoleucine I, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, and leucine L at position 130 is substituted by proline P.

[0542] The coding sequence of the above-mentioned mutant extremely thermophilic PTE has the lactonase activity according to the present invention and is derived from the extremely thermophilic PTE of Sulfolobus solfataricus corresponding to SEQ ID NO: 3 and corresponding to the following sequences SEQ ID NO: 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, and the mutant extremely thermophilic PTE is also part of the present invention.

[0543] In addition, the present invention also relates to a mutant hyperthermophilic PTE having the lactonase activity according to the present invention and derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to SEQ ID NO: 3, wherein the mutant hyperthermophilic PTE corresponds to the following sequences SEQ ID NO: 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179, and their respective coding sequences SEQ ID NO: 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176 and 178.

[0544] A more specific subject of the present invention is the above-mentioned mutant hyperthermophilic PTE with lactonase activity, wherein at least one amino acid involved in the salt bridge is modified by substitution or deletion, so that the activation temperature of the mutant hyperthermophilic PTE with lactonase activity is reduced compared to the activation temperature of the mutant hyperthermophilic PTE with lactonase activity in which the amino acid involved in the salt bridge is unmodified.

[0545] "Substitution" refers to the replacement of one amino acid by another. "Deletion" refers to the removal of amino acids, such that the protein sequence that has undergone the deletion is shorter than the sequence that has not undergone the deletion.

[0546] In a preferred embodiment, the amino acids involved in the above-mentioned salt bridges can be replaced by at least 2 amino acids. This is called "addition", and the protein sequence that undergoes the addition is longer than the sequence that does not undergo the addition.

[0547] The substitutions defined according to the invention equally relate to natural or non-natural (artificial) amino acids. Thus, the amino acids involved in the salt bridge can be replaced by natural or artificial amino acids.

[0548] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus solfataricus corresponding to the sequence SEQ ID NO:3, and further comprises at least one mutation corresponding to at least one amino acid of the following amino acid pairs being replaced by another natural or non-natural amino acid, and the positions of the amino acid pairs in SEQ ID NO:3 are as follows: 2R / 314S, 14K / 12E, 26R / 75D, 26R / 42E, 33R / 42E, 33R / 45E, 55R / 52E, 55R / 285E, 74R / 121D, 81K / 42E, 81K / 43D, 84K / 80E, 109R / 113E, 123K / 162E, 147K / 148D, 151K / 148D, 154R / 150E, 154R / 15 87E, 154R / 188E, 161K / 188E, 183R / 150E, 183R / 187E, 183R / 180E, 210K / 245D, 215K / 214D, 223R / 256D, 223 R / 202D, 234K / 204D, 235R / 202D, 241R / 245D, 245D / 244K, 250K / 249D, 277R / 286D, 292K / 298E, 310K / 307E.

[0549] In addition, the present invention also relates to the above-mentioned mutant extremely thermophilic PTE, which has lactonase activity and is derived from the extremely thermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO:5, wherein the mutant PTE comprises at least one mutation selected from the following: in SEQ ID NO:5, glycine G at position 8, lysine K at position 9, valine V at position 28, leucine L at position 47, lysine K at position 55, proline P at position 68, threonine T at position 69, leucine L at position 73, isoleucine I at position 77, valine V at position 84, tyrosine Y at position 98, tyrosine Y at position 100, isoleucine I at position 123, asparagine N at position 131, Aspartic acid D at position 142, asparagine N at position 165, isoleucine I at position 168, aspartic acid D at position 192, glycine G at position 194, arginine R at position 224, glycine G at position 226, leucine L at position 227, leucine L at position 229, phenylalanine F at position 230, leucine L at position 231, tyrosine Y at position 258, cysteine ​​C at position 259, Cysteine ​​C at position 0, Threonine T at position 261, Isoleucine I at position 262, Aspartic acid D at position 263, Tryptophan W at position 264, Glycine G at position 265, Isoleucine I at position 266, Alanine A at position 267, Lysine K at position 268, Proline P at position 269, Glutamic acid E at position 270, Tyrosine Y at position 271, Lysine K at position 272, Proline at position 273 Acid P at position 274, lysine K at position 275, leucine L at position 276, alanine A at position 276, proline P at position 277, lysine K at position 278, tryptophan W at position 279, serine S at position 280, methionine M at position 281, serine S at position 282, leucine L at position 283, isoleucine I at position 284 and threonine T at position 298 are substituted with any other natural or non-natural amino acids.

[0550] In a more specific embodiment, the above-mentioned mutant hyperthermophilic PTE has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence of SEQ ID NO:5, and the mutant hyperthermophilic PTE comprises at least one mutation selected from the following: in SEQ ID NO:5, valine V at position 28, proline P at position 68, threonine T at position 69, leucine L at position 73, tyrosine Y at position 98, tyrosine Y at position 100, aspartic acid D at position 142, arginine R at position 224, glycine G at position 226, leucine L at position 227, phenylalanine F at position 230, cysteine ​​C at position 259, tryptophan W at position 264 and tryptophan W at position 279 are substituted by any other natural or non-natural amino acids.

[0551] In an even more specific embodiment, the above-mentioned mutant hyperthermophilic PTE has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence of SEQ ID NO:5, and comprises only one mutation selected from: in SEQ ID NO:5, valine V at position 28, proline P at position 68, threonine T at position 69, leucine L at position 73, aspartic acid D at position 142, glycine G at position 226, leucine L at position 227, phenylalanine F at position 230, tryptophan W at position 264 and tryptophan W at position 279 are substituted by any other natural or non-natural amino acid.

[0552] In a more specific embodiment, the above-mentioned mutant hyperthermophilic PTE has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence of SEQ ID NO:5, and contains only one mutation selected from: in SEQ ID NO:5, glycine G at position 8, lysine K at position 9, leucine L at position 47, lysine K at position 55, isoleucine I at position 77, valine V at position 84, isoleucine I at position 123, asparagine N at position 131, asparagine N at position 165, isoleucine I at position 168, aspartic acid D at position 192, glycine G at position 194, leucine L at position 229, leucine L at position 231, tyrosine Y at position 258, cysteine ​​C at position 260, threonine T at position 261, isoleucine I at position 262, aspartic acid D at position 263, glycine G at position 265, Isoleucine I at position 266, alanine A at position 267, lysine K at position 268, proline P at position 269, glutamic acid E at position 270, tyrosine Y at position 271, lysine K at position 272, proline P at position 273, lysine K at position 274, leucine L at position 275, alanine A at position 276, proline P at position 277, lysine K at position 278, serine S at position 280, methionine M at position 281, serine S at position 282, leucine L at position 283, isoleucine I at position 284 and threonine T at position 298 are substituted with any other natural or non-natural amino acids.

[0553] In an even more specific embodiment, the mutant hyperthermophilic PTE described above has lactonase activity, is derived from a hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence of SEQ ID NO:5, and comprises only one mutation selected from the group consisting of: glycine G at position 8, lysine K at position 9, leucine L at position 47, lysine K at position 55, isoleucine I at position 77, valine V at position 84, isoleucine I at position 123, asparagine N at position 131, asparagine N at position 165, isoleucine I at position 168, aspartic acid D at position 192, glycine G at position 194, leucine L at position 229, leucine L at position 231, tyrosine Y at position 258, cysteine ​​C at position 260, threonine T at position 261, isoleucine I at position 262, aspartic acid D at position 263, glycine G at position 265, Isoleucine I at position 266, alanine A at position 267, lysine K at position 268, proline P at position 269, glutamic acid E at position 270, tyrosine Y at position 271, lysine K at position 272, proline P at position 273, lysine K at position 274, leucine L at position 275, alanine A at position 276, proline P at position 277, lysine K at position 278, serine S at position 280, methionine M at position 281, serine S at position 282, leucine L at position 283, isoleucine I at position 284 and threonine T at position 298 are substituted with any other natural or non-natural amino acids.

[0554] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and wherein at least one mutation is selected from:

[0555] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0556] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0557] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0558] - the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0559] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0560] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0561] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0562] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0563] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0564] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0565] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0566] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0567] - the asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0568] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0569] - the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0570] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0571] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0572] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0573] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0574] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0575] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0576] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0577] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0578] - the tryptophan W at position 264 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0579] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0580] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0581] - the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLFGAPWYC, in particular TYP, especially T,

[0582] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0583] - and the threonine T at position 298 is substituted by a polar amino acid selected from WYSCQNRKHDE, in particular QS, especially S.

[0584] These 29 specific substitutions in positions G8, K9, V28, L47, K55, T69, L73, I77, V84, Y98, Y100, I123, N131, D142, N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, M281, L283 and T298 belong to the seventh group of substitutions, referred to as Group 7.

[0585] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and wherein at least one mutation is selected from:

[0586] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0587] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0588] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0589] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0590] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0591] - the aspartic acid D at position 263 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0592] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0593] - the isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSN, in particular VWP, especially V,

[0594] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0595] - the lysine K at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0596] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0597] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0598] - the tyrosine Y at position 271 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0599] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0600] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0601] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0602] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0603] - the lysine K at position 278 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular DNQ, especially DN,

[0604] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0605] - the serine S at position 282 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0606] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0607] These 21 specific substitutions in positions I168, D192, Y258, C260, T261, D263, G265, I266, A267, K268, P269, E270, Y / L271, K272, P273, K274, P277, K278, S280, S282 and I284 belong to the eighth group of substitutions referred to as Group 8.

[0608] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and wherein at least one mutation is selected from:

[0609] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0610] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0611] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0612] These three specific substitutions in positions P68, G226 and W279 belong to the ninth group of substitutions referred to as Group 9.

[0613] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and wherein at least one mutation is selected from:

[0614] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0615] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0616] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0617] - the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0618] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0619] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0620] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0621] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0622] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0623] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0624] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0625] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0626] - the asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0627] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0628] - the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0629] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0630] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0631] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0632] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0633] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0634] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0635] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0636] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0637] - the tryptophan W at position 264 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0638] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0639] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0640] - the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILFGAPWYC, in particular TYP, especially T,

[0641] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0642] - and the threonine T at position 298 is substituted by a polar amino acid selected from WYSCQNRKHDE, in particular QS, especially S,

[0643] Further comprising at least one mutation selected from:

[0644] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0645] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0646] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0647] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0648] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0649] - the aspartic acid D at position 263 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0650] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0651] - the isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSTN, in particular VWP, especially V,

[0652] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0653] - the lysine K at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0654] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0655] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0656] - the tyrosine Y at position 271 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0657] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0658] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0659] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0660] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0661] - the lysine K at position 278 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular DNQ, especially DN,

[0662] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0663] - the serine S at position 282 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0664] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0665] This means that the 29 components of group 7 are in positions G8, K9, V28, L47, K55, T69, L73, I77, V84, Y98, Y100, I123, N131, D142, N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, M281, L283, and T298. At least one of the substitutions in the body can be associated with at least one of the 21 specific substitutions in Group 8 in positions I168, D192, Y258, C260, T261, D263, G265, I266, A267, K268, P269, E270, Y / L271, K272, P273, K274, P277, K278, S280, S282 and I284.

[0666] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and wherein at least one mutation is selected from:

[0667] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0668] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0669] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0670] - the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0671] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0672] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0673] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0674] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0675] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0676] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0677] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0678] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0679] - the asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0680] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0681] - the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0682] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0683] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0684] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0685] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0686] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0687] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0688] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0689] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0690] - the tryptophan W at position 264 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0691] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0692] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0693] - the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILFGAPWYC, in particular TYP, especially T,

[0694] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0695] - and the threonine T at position 298 is substituted by a polar amino acid selected from WYSCQNRKHDE, in particular QS, especially S,

[0696] Further comprising at least one mutation selected from:

[0697] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0698] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0699] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0700] This means that at least one of the 29 specific substitutions of group 7 in positions G8, K9, V28, L47, K55, T69, L73, I77, V84, Y98, Y100, I123, N131, D142, N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, M281, L283 and T298 can be associated with at least one of the 3 specific substitutions of group 9 in positions P68, G226 and W279.

[0701] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and wherein at least one mutation is selected from:

[0702] - the glycine G at position 8 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0703] - the lysine K at position 9 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0704] - the valine V at position 28 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0705] - the leucine L at position 47 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0706] - the lysine K at position 55 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0707] - the threonine T at position 69 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0708] - the leucine L at position 73 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0709] - the isoleucine I at position 77 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0710] - the valine V at position 84 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0711] - the tyrosine Y at position 98 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0712] - the tyrosine Y at position 100 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0713] - the isoleucine I at position 123 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0714] - the asparagine N at position 131 is substituted by a non-bulky amino acid selected from GPLIVADCSTN, in particular PST, especially P,

[0715] - the aspartic acid D at position 142 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0716] - the asparagine N at position 165 is substituted by a polar amino acid selected from WYSTCQRKHDE, in particular QR,

[0717] - the glycine G at position 194 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0718] - the arginine R at position 224 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0719] - the leucine L at position 227 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0720] - the leucine L at position 229 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0721] - the phenylalanine F at position 230 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0722] - the leucine L at position 231 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0723] - the cysteine ​​C at position 259 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0724] - the isoleucine I at position 262 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0725] - the tryptophan W at position 264 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0726] - the leucine L at position 275 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0727] - the alanine A at position 276 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0728] - the methionine M at position 281 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILFGAPWYC, in particular TYP, especially T,

[0729] - the leucine L at position 283 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0730] - and the threonine T at position 298 is substituted by a polar amino acid selected from WYSCQNRKHDE, in particular QS, especially S,

[0731] Further comprising at least one mutation selected from:

[0732] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0733] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0734] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0735] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0736] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0737] - the aspartic acid D at position 263 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0738] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0739] - the isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSTN, in particular VWP, especially V,

[0740] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0741] - the lysine K at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0742] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0743] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0744] - the tyrosine Y at position 271 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0745] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0746] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0747] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0748] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0749] - the lysine K at position 278 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular DNQ, especially DN,

[0750] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0751] - the serine S at position 282 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0752] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[0753] Further comprising at least one mutation selected from:

[0754] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0755] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0756] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0757] This means that at least one of the 29 specific substitutions of Group 7 in positions G8, K9, V28, L47, K55, T69, L73, I77, V84, Y98, Y100, I123, N131, D142, N165, G194, R224, L227, L229, F230, L231, C259, I262, W264, L275, A276, M281, L283 and T298 can be replaced by at least one substitution in position I 168, D192, Y258, C260, T261, D263, G265, I266, A267, K268, P269, E270, Y / L271, K272, P273, K274, P277, K278, S280, S282 and I284, and at least one of the 3 specific substitutions in group 9 in positions P68, G226 and W279.

[0758] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and wherein at least one mutation is selected from:

[0759] - the isoleucine I at position 168 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0760] - the aspartic acid D at position 192 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0761] - the tyrosine Y at position 258 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0762] - the cysteine ​​C at position 260 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0763] - the threonine T at position 261 is substituted by a non-bulky amino acid selected from the group consisting of GPLIVADCSN or by a polar amino acid selected from the group consisting of WYSCQNRKHE, in particular GH, especially G,

[0764] - the aspartic acid D at position 263 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVACSTN, in particular SLH,

[0765] - the glycine G at position 265 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0766] - the isoleucine I at position 266 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC or by a non-bulky amino acid selected from GPLVADCSTN, in particular VWP, especially V,

[0767] - the alanine A at position 267 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0768] - the lysine K at position 268 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0769] - the proline P at position 269 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0770] - the glutamic acid E at position 270 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0771] - the tyrosine Y at position 271 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VAL,

[0772] - the lysine K at position 272 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0773] - the proline P at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0774] - the lysine K at position 274 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0775] - the proline P at position 277 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0776] - the lysine K at position 278 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular DNQ, especially DN,

[0777] - the serine S at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0778] - the serine S at position 282 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0779] - and the isoleucine I at position 284 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[0780] Further comprising at least one mutation selected from:

[0781] - the proline P at position 68 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0782] - the glycine G at position 226 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0783] - and the tryptophan W at position 279 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0784] This means that at least one of the 21 specific substitutions of group 8 in positions I168, D192, Y258, C260, T261, D263, G265, I266, A267, K268, P269, E270, Y / L271, K272, P273, K274, P277, K278, S280, S282 and I284 can be associated with at least one of the 3 specific substitutions of group 9 in positions P68, G226 and W279.

[0785] A more specific subject of the present invention is a mutant hyperthermophilic PTE having a lactonase activity according to the invention, derived from a hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, said mutant hyperthermophilic PTE corresponding to the following sequence:

[0786] - SEQ ID NO:51 corresponding to SEQ ID NO:5 comprises the following 1 mutation: tryptophan W at position 264 is substituted by phenylalanine F,

[0787] - SEQ ID NO:53 corresponding to SEQ ID NO:5 comprises the following 1 mutation: tryptophan W at position 264 is substituted by methionine M,

[0788] - SEQ ID NO:55 corresponding to SEQ ID NO:5 comprises the following 1 mutation: tryptophan W at position 264 is substituted by leucine L,

[0789] - SEQ ID NO:57 corresponding to SEQ ID NO:5 comprises the following 1 mutation: tryptophan W at position 264 is substituted by alanine A,

[0790] - SEQ ID NO:59 corresponding to SEQ ID NO:5 comprises the following 1 mutation: tryptophan W at position 264 is substituted by isoleucine I,

[0791] - SEQ ID NO:61 corresponding to SEQ ID NO:5 comprises the following 1 mutation: tryptophan W at position 264 is replaced by valine V,

[0792] - SEQ ID NO:63 corresponding to SEQ ID NO:5 comprises the following 1 mutation: tryptophan W at position 264 is replaced by threonine T,

[0793] - SEQ ID NO:65 corresponding to SEQ ID NO:5 comprises the following three mutations: cysteine ​​C at position 259 is substituted by leucine L, isoleucine I at position 262 is substituted by phenylalanine F, tryptophan W at position 264 is substituted by alanine A,

[0794] - SEQ ID NO:67 corresponding to SEQ ID NO:5 comprises the following 4 mutations: valine V at position 28 is substituted by alanine A, tyrosine Y at position 98 is substituted by tryptophan W, leucine L at position 229 is substituted by methionine M, tryptophan W at position 264 is substituted by methionine M,

[0795] - SEQ ID NO:69 corresponding to SEQ ID NO:5 comprises the following 4 mutations: valine V at position 28 is substituted by alanine A, tyrosine Y at position 98 is substituted by tryptophan W, tryptophan W at position 264 is substituted by leucine L, methionine M at position 281 is substituted by threonine T,

[0796] - SEQ ID NO:71 corresponding to SEQ ID NO:5 comprises the following 4 mutations: cysteine ​​C at position 259 is substituted by alanine A, tryptophan W at position 264 is substituted by methionine M, methionine M at position 281 is substituted by threonine T,

[0797] - SEQ ID NO:73 corresponding to SEQ ID NO:5 comprises the following 6 mutations: valine V at position 28 is substituted by alanine A, isoleucine I at position 77 is substituted by threonine T, tyrosine Y at position 98 is substituted by tryptophan W, tyrosine Y at position 100 is substituted by phenylalanine F, asparagine N at position 131 is substituted by proline P, leucine L at position 227 is substituted by valine V,

[0798] - SEQ ID NO:75 corresponding to SEQ ID NO:5 comprises the following 6 mutations: leucine L at position 73 is substituted by isoleucine I, tyrosine Y at position 100 is substituted by phenylalanine F, isoleucine I at position 123 is substituted by leucine L, leucine L at position 229 is substituted by methionine M, phenylalanine F at position 230 is substituted by serine S, tryptophan W at position 264 is substituted by leucine L,

[0799] - SEQ ID NO:77 corresponding to SEQ ID NO:5 comprises the following 7 mutations: threonine T at position 69 is substituted by serine S, leucine L at position 73 is substituted by isoleucine I, asparagine N at position 131 is substituted by proline P, leucine L at position 229 is substituted by methionine M, phenylalanine F at position 230 is substituted by serine S, tryptophan W at position 264 is substituted by methionine M, leucine L at position 275 is substituted by proline P,

[0800] - SEQ ID NO:79 corresponding to SEQ ID NO:5 comprises the following 6 mutations: threonine T at position 69 is substituted by serine S, isoleucine I at position 77 is substituted by threonine T, tyrosine Y at position 98 is substituted by tryptophan W, tyrosine Y at position 100 is substituted by phenylalanine F, leucine L at position 229 is substituted by methionine M, tryptophan W at position 264 is substituted by leucine L,

[0801] - SEQ ID NO:81 corresponding to SEQ ID NO:5 comprises the following five mutations: lysine K at position 9 is substituted by glutamic acid E, tyrosine Y at position 98 is substituted by tryptophan W, tyrosine Y at position 100 is substituted by phenylalanine F, leucine L at position 229 is substituted by methionine M,

[0802] - SEQ ID NO:83 corresponding to SEQ ID NO:5 comprises the following two mutations: leucine L at position 73 is substituted by isoleucine I, tryptophan W at position 264 is substituted by phenylalanine F,

[0803] - SEQ ID NO:85 corresponding to SEQ ID NO:5 comprises the following 5 mutations: threonine T at position 69 is substituted by serine S, tyrosine Y at position 98 is substituted by tryptophan W, tyrosine Y at position 100 is substituted by phenylalanine F, asparagine N at position 131 is substituted by proline P, leucine L at position 229 is substituted by methionine M,

[0804] - SEQ ID NO:87 corresponding to SEQ ID NO:5 comprises the following 4 mutations: valine V at position 28 is substituted by alanine A, leucine L at position 227 is substituted by valine V, tryptophan W at position 264 is substituted by leucine L,

[0805] - SEQ ID NO:89 corresponding to SEQ ID NO:5 comprises the following 8 mutations: proline P at position 68 is substituted by valine V, threonine T at position 69 is substituted by serine S, tyrosine Y at position 98 is substituted by tryptophan W, tyrosine Y at position 100 is substituted by phenylalanine F, leucine L at position 229 is substituted by methionine M, cysteine ​​C at position 259 is substituted by alanine A, tryptophan W at position 264 is substituted by leucine L, methionine M at position 281 is substituted by threonine T,

[0806] - SEQ ID NO:91 corresponding to SEQ ID NO:5 comprises the following 8 mutations: threonine T at position 69 is substituted by serine S, tyrosine Y at position 98 is substituted by tryptophan W, tyrosine Y at position 100 is substituted by phenylalanine F, asparagine N at position 131 is substituted by proline P, leucine L at position 227 is substituted by valine V, tryptophan W at position 264 is substituted by methionine M,

[0807] -SEQ ID NO:93 corresponding to SEQ ID NO:5 comprises the following 5 mutations: threonine T at position 69 is substituted by serine S, leucine L at position 73 is substituted by isoleucine I, tyrosine Y at position 98 is substituted by tryptophan W, tyrosine Y at position 100 is substituted by phenylalanine F, and asparagine N at position 131 is substituted by proline P.

[0808] In addition, the coding sequence of the above-mentioned mutant hyperthermophilic PTE is also part of the present invention, wherein the mutant hyperthermophilic PTE has the lactonase activity according to the present invention and is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5 and corresponding to the following sequences SEQ ID NO: 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90 and 92.

[0809] In addition, the present invention also relates to a mutant hyperthermophilic PTE having the lactonase activity according to the present invention, which is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius corresponding to the sequence SEQ ID NO: 5, and the protein of the mutant hyperthermophilic PTE corresponds to the following sequences SEQ ID NO: 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 21, 213, 215, 217, 219, 221 and 223, and their respective coding sequences SEQ ID NO: 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220 and 222.

[0810] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus acidocaldarius according to the sequence of SEQ ID NO:5, and further comprises at least one mutation corresponding to at least one amino acid of the following amino acid pairs being replaced by another natural or non-natural amino acid, and the positions of the amino acid pairs in SEQ ID NO:5 are as follows: 3K / 315S, 15G / 13S, 27R / 76D, 27R / 43E, 34R / 43E, 34R / 46E, 56T / 53E, 56T / 286T, 75R / 122D, 82K / 43E, 82K / 44D, 85K / 81E, 110R / 114E, 124K / 163E, 148R / 149D, 152R / 149D, 155R / 151E, 155R / 186T 8E, 155R / 189E, 162K / 189E, 184R / 151E, 184R / 188E, 184R / 181E, 211K / 246D, 216K / 215D, 224R / 257D, 224 R / 203D, 235K / 205D, 236R / 203D, 242K / 246D, 246D / 245K, 251R / 250D, 278K / 287D, 293K / 299D, 311A / 308K.

[0811] In addition, the present invention relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity and is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, wherein the mutant PTE comprises at least one mutation selected from the group consisting of: SEQ ID NO: NO:7, glycine G at position 7, lysine K at position 8, valine V at position 27, leucine L at position 46, lysine K at position 54, proline P at position 67, threonine T at position 68, leucine L at position 72, isoleucine I at position 76, valine V at position 83, tyrosine Y at position 97, tyrosine Y at position 99, isoleucine I at position 122, serine S at position 130, aspartic acid D at position 141, lysine K at position 164, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, arginine R at position 223, glycine G at position 225, leucine L at position 226, leucine L at position 228, phenylalanine F at position 229, leucine L at position 230, tyrosine Y at position 257, cysteine ​​C at position 258, 277 arginine R, 278 tryptophan W, 279 serine S, 280 methionine M, 281 alanine A, 282 serine S, 283 isoleucine I, 294 glycine G, 295 threonine T, 296 alanine A, 297 arginine R, 298 proline P, 299 glutamic acid E, 270 leucine L, 271 lysine K, 272 proline P, 273 lysine K, 274 leucine L, 275 alanine A, 276 proline P, 277 arginine R, 278 tryptophan W, 299 serine S, 280 methionine M, 281 alanine A, 282 serine S, 283 isoleucine I and 297 serine S are substituted with any other natural or non-natural amino acids.

[0812] In a more specific embodiment, the above-mentioned mutant hyperthermophilic PTE has lactonase activity and is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO:7, wherein the mutant hyperthermophilic PTE comprises at least one mutation selected from the following: in SEQ ID NO:7, valine V at position 27, proline P at position 67, threonine T at position 68, leucine L at position 72, tyrosine Y at position 97, tyrosine Y at position 99, aspartic acid D at position 141, arginine R at position 223, glycine G at position 225, leucine L at position 226, phenylalanine F at position 229, cysteine ​​C at position 258, tryptophan W at position 263 and tryptophan W at position 278 are substituted by any other natural or non-natural amino acids.

[0813] In an even more specific embodiment, the above-mentioned mutant extremely thermophilic PTE has lactonase activity, is derived from the extremely thermophilic PTE corresponding to the sequence of SEQ ID NO:7, and contains only one mutation, wherein the mutation is selected from: in SEQ ID NO:7, valine V at position 27, proline P at position 67, threonine T at position 68, leucine L at position 72, aspartic acid D at position 141, glycine G at position 225, leucine L at position 226, phenylalanine F at position 229, tryptophan W at position 263 and tryptophan W at position 278 are replaced by any other natural or non-natural amino acid.

[0814] In an even more specific embodiment, the mutant hyperthermophilic PTE described above has lactonase activity, is derived from a hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence of SEQ ID NO:7, and comprises at least one mutation selected from the group consisting of: in SEQ ID NO:7, glycine G at position 7, lysine K at position 8, leucine L at position 46, lysine K at position 54, isoleucine I at position 76, valine V at position 83, isoleucine I at position 122, serine S at position 130, lysine K at position 164, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, leucine L at position 228, leucine L at position 230, tyrosine Y at position 257, cysteine ​​C at position 259, threonine T at position 260, isoleucine I at position 261, aspartic acid D at position 262, glycine G at position 264, Threonine T at position 265, alanine A at position 266, arginine R at position 267, proline P at position 268, glutamic acid E at position 269, leucine L at position 270, lysine K at position 271, proline P at position 272, lysine K at position 273, leucine L at position 274, alanine A at position 275, proline P at position 276, arginine R at position 277, serine S at position 279, methionine M at position 280, alanine A at position 281, leucine L at position 282, isoleucine I at position 283 and serine S at position 297 are substituted with any other natural or non-natural amino acids.

[0815] In an even more specific embodiment, the mutant hyperthermophilic PTE has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence of SEQ ID NO:7, and comprises only one mutation selected from the group consisting of: glycine G at position 7, lysine K at position 8, leucine L at position 46, lysine K at position 54, isoleucine I at position 76, valine V at position 83, isoleucine I at position 122, serine S at position 130, lysine K at position 164, isoleucine I at position 167, aspartic acid D at position 191, glycine G at position 193, leucine L at position 228, leucine L at position 230, tyrosine Y at position 257, cysteine ​​C at position 259, threonine T at position 260, isoleucine I at position 261, aspartic acid D at position 262, glycine G at position 264, Threonine T at position 265, alanine A at position 266, arginine R at position 267, proline P at position 268, glutamic acid E at position 269, leucine L at position 270, lysine K at position 271, proline P at position 272, lysine K at position 273, leucine L at position 274, alanine A at position 275, proline P at position 276, arginine R at position 277, serine S at position 279, methionine M at position 280, alanine A at position 281, leucine L at position 282, isoleucine I at position 283 and serine S at position 297 are substituted with any other natural or non-natural amino acids.

[0816] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and wherein at least one mutation is selected from:

[0817] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0818] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0819] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0820] - the leucine L at position 46 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0821] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0822] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0823] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0824] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0825] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0826] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0827] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0828] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0829] - the serine S at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCTN, in particular PT, especially P,

[0830] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0831] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0832] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0833] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0834] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0835] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0836] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0837] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0838] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0839] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0840] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0841] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0842] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0843] - the methionine M at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TYP, especially T,

[0844] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0845] - and the serine S at position 297 is substituted by a polar amino acid selected from WYTCQNRKHDE, in particular QT.

[0846] These 29 specific substitutions in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, S130, D141, K164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, M280, L282 and N297 belong to the tenth group of substitutions referred to as Group 10.

[0847] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and wherein at least one mutation is selected from:

[0848] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0849] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0850] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0851] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0852] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[0853] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[0854] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0855] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[0856] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0857] - the arginine R at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0858] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0859] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0860] - the leucine L at position 270 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VA,

[0861] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0862] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0863] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0864] - the proline P at position 276 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0865] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[0866] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0867] - the alanine A at position 281 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0868] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0869] These 21 specific substitutions in positions I167, D191, Y257, C259, T260, D262, G264, T265, A266, R267, P268, E269, L270, K271, P272, K273, P276, R277, S279, A281 and I283 belong to the eleventh group of substitutions referred to as Group 11.

[0870] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and wherein at least one mutation is selected from:

[0871] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0872] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0873] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0874] These three specific substitutions in positions P67, G225 and W278 belong to a twelfth group of substitutions referred to as Group 12.

[0875] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and wherein at least one mutation is selected from:

[0876] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0877] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0878] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0879] - the leucine L at position 46 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0880] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0881] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0882] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0883] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0884] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0885] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0886] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0887] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0888] - the serine S at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCTN, in particular PT, especially P,

[0889] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0890] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0891] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0892] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0893] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0894] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0895] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0896] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0897] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0898] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0899] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0900] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0901] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0902] - the methionine M at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TYP, especially T,

[0903] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0904] - and the serine S at position 297 is substituted by a polar amino acid selected from WYTCQNRKHDE, in particular QT,

[0905] Further comprising at least one mutation selected from:

[0906] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0907] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0908] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0909] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0910] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[0911] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[0912] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[0913] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[0914] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[0915] - the arginine R at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[0916] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[0917] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[0918] - the leucine L at position 270 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VA,

[0919] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[0920] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[0921] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[0922] - the proline P at position 276 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[0923] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[0924] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[0925] - the alanine A at position 281 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[0926] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V.

[0927] This means that the 29 specific components of group 10 in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, S130, D141, K164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, M280, L282, and N297 At least one of the substitutions in the body can be associated with at least one of the 21 specific substitutions in Group 11 in positions I167, D191, Y257, C259, T260, D262, G264, T265, A266, R267, P268, E269, L270, K271, P272, K273, P276, R277, S279, A281 and I283.

[0928] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and wherein at least one mutation is selected from:

[0929] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0930] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0931] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0932] - the leucine L at position 46 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0933] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0934] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0935] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0936] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0937] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0938] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0939] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0940] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0941] - the serine S at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCTN, in particular PT, especially P,

[0942] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0943] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0944] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0945] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0946] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0947] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0948] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0949] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0950] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0951] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0952] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0953] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0954] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0955] - the methionine M at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TYP, especially T,

[0956] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0957] - and the serine S at position 297 is substituted by a polar amino acid selected from WYTCQNRKHDE, in particular QT,

[0958] Further comprising at least one mutation selected from:

[0959] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[0960] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[0961] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[0962] This means that at least one of the 29 specific substitutions in group 10 in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, S130, D141, K164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, M280, L282 and N297 can be associated with at least one substitution in K273, P276, R277, S279, A281 and I283, and with at least one of the 3 specific substitutions in group 12 in positions P67, G225 and W278.

[0963] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and wherein at least one mutation is selected from:

[0964] - the glycine G at position 7 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular STA, especially S,

[0965] - the lysine K at position 8 is substituted by a charged amino acid selected from RHDEC, in particular EDR, especially E,

[0966] - the valine V at position 27 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular GIFA, especially A,

[0967] - the leucine L at position 46 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular YW,

[0968] - the lysine K at position 54 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IRL, especially I,

[0969] - the threonine T at position 68 is substituted by a non-bulky amino acid selected from GPLIVADCSN, in particular VAS, especially S,

[0970] - the leucine L at position 72 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular CAMI, especially I,

[0971] - the isoleucine I at position 76 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular PTV, especially T,

[0972] - the valine V at position 83 is substituted by a non-bulky amino acid selected from GPLIADCSTN or by a hydrophobic amino acid selected from ILMFGAPWYC, in particular AGI, especially A,

[0973] - the tyrosine Y at position 97 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular FCLW, especially W,

[0974] - the tyrosine Y at position 99 is substituted by a bulky amino acid selected from EHKRQWFM or by a hydrophobic amino acid selected from VILMFGAPWC, in particular GEWF, especially F,

[0975] - the isoleucine I at position 122 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular LAV, especially L,

[0976] - the serine S at position 130 is substituted by a non-bulky amino acid selected from GPLIVADCTN, in particular PT, especially P,

[0977] - the aspartic acid D at position 141 is substituted by a polar amino acid selected from WYSTCQNRKHE, in particular SET, especially T,

[0978] - the lysine K at position 164 is substituted by a polar amino acid selected from WYSTCQNRHDE, in particular NQR, especially N,

[0979] - the glycine G at position 193 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a polar amino acid selected from WYSTCNQRKHDE, in particular ST, especially S,

[0980] - the arginine R at position 223 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNKHDE, in particular CSTAH, especially AC,

[0981] - the leucine L at position 226 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular AIVH, especially V,

[0982] - the leucine L at position 228 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VIMFGAPWYC, in particular IM, especially M,

[0983] - the phenylalanine F at position 229 is replaced by a non-bulky amino acid selected from GPLIVADCSTN, in particular LTAS, especially S,

[0984] - the leucine L at position 230 is substituted by a non-bulky amino acid selected from GPIVADCSTN, in particular PVA, especially P,

[0985] - the cysteine ​​C at position 258 is substituted by a hydrophobic amino acid selected from VILMFGAPWY, in particular YLIA, especially LA,

[0986] - the isoleucine I at position 261 is substituted by a hydrophobic amino acid selected from VLMFGAPWYC, in particular FWC, especially F,

[0987] - the tryptophan W at position 263 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPYC, in particular ALMFCITV, especially F,

[0988] - the leucine L at position 274 is substituted by a hydrophobic amino acid selected from VIMFGAPWYC, in particular AVP, especially P,

[0989] - the alanine A at position 275 is substituted by a hydrophobic amino acid selected from VILMFGPWYC or by a non-bulky amino acid selected from GPLIVDCSTN, in particular NVMT, especially T,

[0990] - the methionine M at position 280 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular TYP, especially T,

[0991] - the leucine L at position 282 is substituted by a bulky amino acid selected from the group consisting of EKHRQYWFM, in particular FMH, especially M,

[0992] - and the serine S at position 297 is substituted by a polar amino acid selected from WYTCQNRKHDE, in particular QT,

[0993] Further comprising at least one mutation selected from:

[0994] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[0995] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[0996] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[0997] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[0998] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[0999] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[1000] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[1001] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[1002] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[1003] - the arginine R at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[1004] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[1005] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[1006] - the leucine L at position 270 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VA,

[1007] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[1008] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[1009] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[1010] - the proline P at position 276 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[1011] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[1012] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[1013] - the alanine A at position 281 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[1014] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[1015] Further comprising at least one mutation selected from:

[1016] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[1017] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[1018] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[1019] This means that at least one of the 29 specific substitutions in group 10 in positions G7, K8, V27, F46, K54, T68, L72, I76, V83, Y97, Y99, I122, S130, D141, K164, G193, R223, L226, L228, F229, L230, C258, I261, W263, L274, A275, M280, L282 and N297 can be replaced by at least one of the 29 specific substitutions in group 10 in positions I1 67, D191, Y257, C259, T260, D262, G264, T265, A266, R267, P268, E269, L270, K271, P272, K273, P276, R277, S279, A281 and I283, and is associated with at least one of the 3 specific substitutions in Group 12 in positions P67, G225 and W278.

[1020] In addition, the present invention also relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and wherein at least one mutation is selected from:

[1021] - the isoleucine I at position 167 is substituted by a non-bulky amino acid selected from GPLVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWYC, in particular VAL, especially V,

[1022] - the aspartic acid D at position 191 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHE, in particular ST, especially S,

[1023] - the tyrosine Y at position 257 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VLMFGAPWC, in particular CSVW, especially C,

[1024] - the cysteine ​​C at position 259 is substituted by a non-bulky amino acid selected from GPLIVADSTN or by a hydrophobic amino acid selected from VILMFGAPWY, in particular SFWV, especially S,

[1025] - the threonine T at position 260 is substituted by a non-bulky amino acid selected from GPLIVADCSN or by a polar amino acid selected from WYSCQNRKHE, in particular GH, especially G,

[1026] - the aspartic acid D at position 262 is substituted by a polar amino acid selected from WYSTCQNRKHE or by a non-bulky amino acid selected from GPLIVADCSTN, in particular SLH,

[1027] - the glycine G at position 264 is substituted by a non-bulky amino acid selected from PLIVADCSTN or by a hydrophobic amino acid selected from VILMFAPWYC, in particular AVP,

[1028] - the threonine T at position 265 is substituted by a hydrophobic amino acid selected from VILMFGAPWYC or by a non-bulky amino acid selected from GPLIVADCSN, in particular VWP, especially V,

[1029] - the alanine A at position 266 is substituted by a polar amino acid selected from WYSTCQNRKHDE, in particular NQ, especially N,

[1030] - the arginine R at position 267 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular IAP, especially IP,

[1031] - the proline P at position 268 is substituted by a hydrophobic amino acid selected from VILMFGAWYC, in particular MCL, especially M,

[1032] - the glutamic acid E at position 269 is substituted by a polar amino acid selected from WYSTCQNRKHD, in particular DQ, especially D,

[1033] - the leucine L at position 270 is substituted by a non-bulky amino acid selected from GPIVADCSTN or by a hydrophobic amino acid selected from VILMFGAPWC, in particular VA,

[1034] - the lysine K at position 271 is substituted by a bulky amino acid selected from EHRQYWFM or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular MLA,

[1035] - the proline P at position 272 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRKHDE, in particular DEL, especially DL,

[1036] - the lysine K at position 273 is substituted by a non-bulky amino acid selected from GPLIVADCSTN or by a polar amino acid selected from WYSTCQNRHD, in particular RP,

[1037] - the proline P at position 276 is substituted by a bulky amino acid selected from EHKRQYWFM or by a hydrophobic amino acid selected from VILMFGAWYC, in particular KAV, especially K,

[1038] - the arginine R at position 277 is substituted by a polar amino acid selected from WYSTCQNKHDE, in particular DNQ, especially DN,

[1039] - the serine S at position 279 is substituted by a non-bulky amino acid selected from GPLIVADCTN or by a polar amino acid selected from WYTCQNRKHDE, in particular GH,

[1040] - the alanine A at position 281 is substituted by a non-bulky amino acid selected from GPLIVDCSTN or by a hydrophobic amino acid selected from VILMFGAPWYC, in particular ALV, especially AL,

[1041] - and the isoleucine I at position 283 is substituted by a non-bulky amino acid selected from GPLVADCSTN, in particular VAL, especially V,

[1042] Further comprising at least one mutation selected from:

[1043] - the proline P at position 67 is substituted by a non-bulky amino acid selected from GLIVADCSTN, in particular GAV,

[1044] - the glycine G at position 225 is substituted by a non-bulky amino acid selected from PLIVADCSTN, in particular AVP,

[1045] - and the tryptophan W at position 278 is substituted by a hydrophobic amino acid selected from VILMFGAPYC or by a charged amino acid selected from RKHDEC, in particular RKDI, especially R.

[1046] This means that at least one of the 21 specific substitutions in group 11 in positions I167, D191, Y257, C259, T260, D262, G264, T265, A266, R267, P268, E269, L270, K271, P272, K273, P276, R277, S279, A281 and I283 can be associated with at least one of the 3 specific substitutions in group 12 in positions P67, G225 and W278.

[1047] A more specific subject of the present invention is a mutant hyperthermophilic PTE having a lactonase activity according to the invention, derived from a hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO: 7, and said hyperthermophilic PTE corresponds to the following sequence:

[1048] - SEQ ID NO:95 corresponding to SEQ ID NO:7 comprises the following 1 mutation: tryptophan W at position 263 is substituted by phenylalanine F,

[1049] - SEQ ID NO:97 corresponding to SEQ ID NO:7 comprises the following 1 mutation: tryptophan W at position 263 is substituted by methionine M,

[1050] - SEQ ID NO:99 corresponding to SEQ ID NO:7 comprises the following 1 mutation: tryptophan W at position 263 is substituted by leucine L,

[1051] - SEQ ID NO: 101 corresponding to SEQ ID NO: 7 comprises the following 1 mutation: tryptophan W at position 263 is substituted by alanine A,

[1052] - SEQ ID NO: 103 corresponding to SEQ ID NO: 7 comprises the following 1 mutation: tryptophan W at position 263 is substituted by isoleucine I,

[1053] - SEQ ID NO: 105 corresponding to SEQ ID NO: 7 comprises the following 1 mutation: tryptophan W at position 263 is replaced by valine V,

[1054] - SEQ ID NO: 107 corresponding to SEQ ID NO: 7 comprises the following 1 mutation: tryptophan W at position 263 is replaced by threonine T,

[1055] - SEQ ID NO: 109 corresponding to SEQ ID NO: 7 comprises the following three mutations: cysteine ​​C at position 258 is substituted by leucine L, isoleucine I at position 261 is substituted by phenylalanine F, tryptophan W at position 263 is substituted by alanine A,

[1056] - SEQ ID NO: 111 corresponding to SEQ ID NO: 7 comprises the following 4 mutations: valine V at position 27 is substituted by alanine A, tyrosine Y at position 97 is substituted by tryptophan W, leucine L at position 228 is substituted by methionine M, tryptophan W at position 263 is substituted by methionine M,

[1057] - SEQ ID NO: 113 corresponding to SEQ ID NO: 7 comprises the following 4 mutations: valine V at position 27 is substituted by alanine A, tyrosine Y at position 97 is substituted by tryptophan W, tryptophan W at position 263 is substituted by leucine L, methionine M at position 280 is substituted by threonine T,

[1058] - SEQ ID NO: 115 corresponding to SEQ ID NO: 7 comprises the following 4 mutations: cysteine ​​C at position 258 is substituted by alanine A, tryptophan W at position 263 is substituted by methionine M, methionine M at position 280 is substituted by threonine T,

[1059] - SEQ ID NO: 117 corresponding to SEQ ID NO: 7 comprises the following 6 mutations: valine V at position 27 is substituted by alanine A, isoleucine I at position 76 is substituted by threonine T, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, serine S at position 130 is substituted by proline P, leucine L at position 226 is substituted by valine V,

[1060] - SEQ ID NO: 119 corresponding to SEQ ID NO: 7 comprises the following 6 mutations: leucine L at position 72 is substituted by isoleucine I, tyrosine Y at position 99 is substituted by phenylalanine F, isoleucine I at position 122 is substituted by leucine L, leucine L at position 228 is substituted by methionine M, phenylalanine F at position 229 is substituted by serine S, tryptophan W at position 263 is substituted by leucine L,

[1061] - SEQ ID NO:121 corresponding to SEQ ID NO:7 comprises the following 7 mutations: threonine T at position 68 is substituted by serine S, leucine L at position 72 is substituted by isoleucine I, serine S at position 130 is substituted by proline P, leucine L at position 228 is substituted by methionine M, phenylalanine F at position 229 is substituted by serine S, tryptophan W at position 263 is substituted by methionine M, leucine L at position 274 is substituted by proline P,

[1062] - SEQ ID NO:123 corresponding to SEQ ID NO:7 comprises the following 6 mutations: threonine T at position 68 is substituted by serine S, isoleucine I at position 76 is substituted by threonine T, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 228 is substituted by methionine M, tryptophan W at position 263 is substituted by leucine L,

[1063] - SEQ ID NO: 125 corresponding to SEQ ID NO: 7 comprises the following 5 mutations: lysine K at position 8 is substituted by glutamic acid E, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 228 is substituted by methionine M,

[1064] - SEQ ID NO: 127 corresponding to SEQ ID NO: 7 comprises the following two mutations: leucine L at position 72 is substituted by isoleucine I, tryptophan W at position 263 is substituted by phenylalanine F,

[1065] - SEQ ID NO: 129 corresponding to SEQ ID NO: 7 comprises the following 5 mutations: threonine T at position 68 is substituted by serine S, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, serine S at position 130 is substituted by proline P, leucine L at position 228 is substituted by methionine M,

[1066] - SEQ ID NO: 131 corresponding to SEQ ID NO: 7 comprises the following 4 mutations: valine V at position 27 is substituted by alanine A, leucine L at position 226 is substituted by valine V, tryptophan W at position 263 is substituted by leucine L,

[1067] - SEQ ID NO:133 corresponding to SEQ ID NO:7 comprises the following 8 mutations: proline P at position 67 is substituted by valine V, threonine T at position 68 is substituted by serine S, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, leucine L at position 228 is substituted by methionine M, cysteine ​​C at position 258 is substituted by alanine A, tryptophan W at position 263 is substituted by leucine L, methionine M at position 280 is substituted by threonine T,

[1068] - SEQ ID NO:135 corresponding to SEQ ID NO:7 comprises the following 8 mutations: threonine T at position 68 is substituted by serine S, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, serine S at position 130 is substituted by proline P, lysine K at position 164 is substituted by asparagine N, leucine L at position 226 is substituted by valine V, tryptophan W at position 263 is substituted by methionine M,

[1069] -SEQ ID NO:137 corresponding to SEQ ID NO:7 comprises the following 5 mutations: threonine T at position 68 is substituted by serine S, leucine L at position 72 is substituted by isoleucine I, tyrosine Y at position 97 is substituted by tryptophan W, tyrosine Y at position 99 is substituted by phenylalanine F, and serine S at position 130 is substituted by proline P.

[1070] In addition, the coding sequence of the above-mentioned mutant extremely thermophilic PTE is also part of the present invention, wherein the mutant extremely thermophilic PTE has the lactonase activity according to the present invention and is derived from the extremely thermophilic PTE of Icelandic Sulfolobus corresponding to the sequence SEQ ID NO:7 and corresponding to the following sequences SEQ ID NO:94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134 and 136.

[1071] In addition, the present invention also relates to a mutant extremely thermophilic PTE, which has the lactonase activity according to the present invention, derived from the extremely thermophilic PTE of Icelandic Sulfolobus corresponding to the sequence SEQ ID NO: 7, and the protein of the mutant extremely thermophilic PTE corresponds to the following sequences SEQ ID NO: 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265 and 267, and their respective coding sequences SEQ ID NO: 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264 and 266.

[1072] The present invention more specifically relates to the above-mentioned mutant hyperthermophilic PTE, which has lactonase activity, is derived from the hyperthermophilic PTE of Sulfolobus icelandica corresponding to the sequence SEQ ID NO:7, and further comprises at least one mutation corresponding to at least one amino acid of the following amino acid pairs being substituted by another natural or non-natural amino acid, and the positions of the amino acid pairs in SEQ ID NO:7 are as follows: 2R / 314S, 14E / 12E, 26R / 75D, 26R / 42E, 33R / 42E, 33R / 45E, 55R / 52E, 55R / 285E, 74R / 121D, 81K / 42E, 81K / 43D, 84K / 80E, 109R / 113E, 123K / 162E, 147K / 148D, 151K / 148D, 154R / 150E, 154R / 18 7E, 154R / 188E, 161K / 188E, 183R / 150E, 183R / 187E, 183R / 180E, 210K / 245D, 215K / 214D, 223R / 256D, 223 R / 202D, 234K / 204D, 235R / 202D, 241K / 245D, 245D / 244K, 250R / 249D, 277R / 286D, 292K / 298E, 310K / 307E.

[1073] In addition, the present invention also relates to a mutant extremely thermophilic phosphotriesterase having lactonase activity, which is derived from the extremely thermophilic phosphotriesterase defined by the consensus sequence SEQ ID NO:1, wherein the mutant extremely thermophilic phosphotriesterase having a single mutation is a substitution of tryptophan W at position 265 in the consensus sequence SEQ ID NO:1.

[1074] In one embodiment, the present invention relates to a mutated extremely thermophilic phosphotriesterase as defined above, wherein the mutated extremely thermophilic phosphotriesterase has a single mutation in which tryptophan W at position 265 in the consensus sequence SEQ ID NO: 1 is replaced by threonine T.

[1075] In one embodiment, the present invention relates to a mutated extremely thermophilic phosphotriesterase as defined above, wherein the mutated extremely thermophilic phosphotriesterase has a single mutation in which the tryptophan W at position 263 of the sequence SEQ ID NO: 3 is replaced by isoleucine I, valine V, threonine T or alanine A.

[1076] Furthermore, the present invention also relates to an isolated nucleic acid sequence encoding a mutated extremely thermophilic PTE having lactonase activity as defined above.

[1077] Furthermore, the subject of the present invention is a vector comprising a nucleic acid encoding a mutant hyperthermophilic PTE having lactonase activity as defined above. Such a vector may be a plasmid, cosmid, phage or any other tool for cloning and expressing nucleic acids.

[1078] In addition, the present invention also relates to host cells, in particular bacteria, transfected with the vector defined above, such that their genome comprises a nucleotide sequence encoding a mutated hyperthermophilic PTE with lactonase activity as defined above, said mutated hyperthermophilic PTE having lactonase activity, produced in the cytoplasm of the host cells or secreted on their surface.

[1079] Furthermore, the subject of the present invention is a method for producing a mutated hyperthermophilic PTE variant having lactonase activity, comprising:

[1080] - introducing a plurality of vectors comprising a nucleic acid sequence encoding a mutated extremely thermophilic PTE having lactonase activity into a population of host cells,

[1081] - cultivating a population of host cells in a suitable culture medium,

[1082] - expressing said polynucleotide in said cultured host cell,

[1083] -Recovery of multiple mutant extremely thermophilic PTE variants.

[1084] Furthermore, the present invention also relates to a library of mutant hyperthermophilic PTE variants having lactonase activity, which is obtained by the method for generating the library of mutant hyperthermophilic PTE having lactonase activity disclosed above.

[1085] The purpose of the library is to provide polypeptide variants of mutant hyperthermophilic PTEs having lactonase activity which have enhanced phenotypic properties relative to the wild-type hyperthermophilic PTE having lactonase activity from which the mutant hyperthermophilic PTEs are derived.

[1086] In addition, the present invention also relates to the use of a mutation that increases the lactonase catalytic activity of an extremely thermophilic phosphotriesterase, wherein the extremely thermophilic phosphotriesterase has a sequence corresponding to the consensus sequence of SEQ ID NO: 1, wherein the amino acid W at position 265 is substituted by an amino acid selected from isoleucine I, valine V, threonine T or alanine A, thereby obtaining a mutated extremely thermophilic phosphotriesterase, which has an increased lactonase catalytic activity compared to the lactonase activity of the extremely thermophilic phosphotriesterase corresponding to the consensus sequence of SEQ ID NO: 1.

[1087] The present invention also relates to the use of a single mutation that increases the lactonase catalytic activity of an extremely thermophilic phosphotriesterase, wherein the extremely thermophilic phosphotriesterase has a sequence corresponding to the consensus sequence of SEQ ID NO: 1, wherein the amino acid W at position 265 is substituted by an amino acid selected from isoleucine I, valine V, threonine T or alanine A, thereby obtaining a mutant extremely thermophilic phosphotriesterase, which has an increased lactonase catalytic activity compared to the lactonase activity of the extremely thermophilic phosphotriesterase corresponding to the consensus sequence of SEQ ID NO: 1.

[1088] The present invention also relates to a method for increasing the lactonase catalytic activity of an extremely thermophilic phosphotriesterase, wherein the extremely thermophilic phosphotriesterase has a sequence corresponding to the consensus sequence of SEQ ID NO: 1, wherein the method comprises the step of replacing the amino acid W at position 265 with an amino acid selected from isoleucine I, valine V, threonine T or alanine A, thereby obtaining a mutant extremely thermophilic phosphotriesterase, wherein the mutant extremely thermophilic phosphotriesterase has an increased lactonase catalytic activity compared to the lactonase activity of the extremely thermophilic phosphotriesterase corresponding to the consensus sequence of SEQ ID NO: 1.

[1089] The present invention also relates to a method for increasing the lactonase catalytic activity of an extremely thermophilic phosphotriesterase, wherein the extremely thermophilic phosphotriesterase has a sequence corresponding to the consensus sequence of SEQ ID NO: 1, wherein the method comprises the step of singly substituting the amino acid W at position 265 with an amino acid selected from isoleucine I, valine V, threonine T or alanine A, thereby obtaining a mutant extremely thermophilic phosphotriesterase, wherein the mutant extremely thermophilic phosphotriesterase has an increased lactonase catalytic activity compared to the lactonase activity of the extremely thermophilic phosphotriesterase corresponding to the consensus sequence of SEQ ID NO: 1.

[1090] The expression "lactonase catalytic activity" refers to the hydrolysis of lactones, in particular N-acyl homoserine lactones (AHLs), which mediate bacterial communication in many Gram-negative bacteria and some archaeal organisms.

[1091] The expression "increased catalytic activity of lactonase" means that, for the hydrolysis of AHL, the K of the non-mutated hyperthermophilic PTE from which the mutated hyperthermophilic PTE is derived is increased. cat / K M Compared with the ratio, the mutant extreme thermophilic PTE has a higher K cat / K M ratio.

[1092] Preferably, the K of the mutated hyperthermophilic PTE is greater than that of the non-mutated hyperthermophilic PTE. cat / K MThe increase is at least 2 times, more preferably 25 to 70 times.

[1093] In one embodiment, the invention relates to the use or method as defined above, wherein said extremely thermophilic phosphotriesterase is a wild-type extremely thermophilic phosphotriesterase.

[1094] In one embodiment, the present invention relates to the use or method as defined above, wherein the mutated extreme thermophilic phosphotriesterase increases the hydrolysis of 3-oxo-C12AHL by at least 2 times, in particular 25 to 70 times, compared to the hydrolysis of 3-oxo-C12AHL by the extreme thermophilic phosphotriesterase.

[1095] Preferably, the K of the mutated hyperthermophilic PTE is greater than that of the non-mutated hyperthermophilic PTE. cat / K M The increase is at least 2 times, more preferably 25 to 70 times.

[1096] In one embodiment, the invention relates to a use or a method as defined above, wherein said mutated extremely thermophilic phosphotriesterase has a thermostability which is substantially similar to the thermostability of said extremely thermophilic phosphotriesterase.

[1097] The expression "thermostability" refers to the ability of PTE to resist high temperatures, in particular above 70° C., more in particular 70° C. to 120° C. At these temperatures, the 3D structure of PTE is maintained and the enzymes are still active and able to hydrolyze OP or lactones.

[1098] Traditionally, mutations that modify the catalytic activity of PTEs are associated with a loss of thermostability in the mutated PTE compared to the non-mutated PTE. However, the mutated PTEs of the present invention have a thermostability substantially similar to that of the extremely thermophilic phosphotriesterases.

[1099] The thermal stability of PTE can be verified by measuring the melting temperature.

[1100] The melting temperature of the mutant PTE of the present invention is higher than 80°C, preferably higher than 85°C, preferably higher than 90°C.

[1101] The melting temperature can be measured by circular dichroism spectroscopy.

[1102] In one embodiment, the invention relates to a use or a method as defined above, wherein the amino acid at position 2 in SEQ ID NO: 1 is deleted.

[1103] In one embodiment, the present invention relates to the use or method as defined above, wherein the extremely thermophilic phosphotriesterase is selected from: SEQ ID NO: 3 obtained from Sulfolobus solfataricus, SEQ ID NO: 5 obtained from Sulfolobus acidocalaricus, or SEQ ID NO: 7 obtained from Sulfolobus acidocalaricus, wherein the sequences SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 belong to the common SEQ ID NO: 1, SEQ ID NO: 5 lacks the amino acid at position 2 in SEQ ID NO: 1, and SEQ ID NO: 3 and SEQ ID NO: 7 lack the amino acids at positions 2 and 3 in SEQ ID NO: 1.

[1104] In one embodiment, the invention relates to a use or a method as defined above, wherein at least the amino acid W at position 265 is substituted by an amino acid selected from Isoleucine I, Valine V, Threonine T or Alanine A.

[1105] In one embodiment, the invention relates to a use or a method as defined above, wherein said amino acid W at position 265 is substituted by Isoleucine I.

[1106] In one embodiment, the invention relates to the use or method as defined above, wherein the mutant extremely thermophilic phosphotriesterase further comprises at least one additional substitution selected from the group consisting of: in SEQ ID NO: 1, positions G9, K10, V29, F / L48, K56, P69, T70, L74, I78, V85, I124, L / S / N132, D143, K / N166, I169, D193, G195, G227, L228, L230, F231, L232, Y259, C261, T262, I264, 3. Replacement of D264, G266, T / I267, A268, K / R269, P270, E271, Y / L272, K273, P274, K275, L276, A277, P278, R / K279, W280, S281, I / M282, T / A / S283, L284, I285, and N / S / T299.

[1107] In one embodiment, the invention relates to the use or method as defined above, wherein the mutant extremely thermophilic phosphotriesterase further comprises at least one additional substitution selected from the group consisting of: in SEQ ID NO: 1, positions G9, K10, V29, F / L48, K56, P69, T70, L74, I78, V85, I124, L / S / N132, D143, K / N166, I169, D193, G195, G227, L228, L230, F231, L232, Y259, C261, T262 , I263, D264, G266, T / I267, A268, K / R269, P270, E271, Y / L272, K273, P274, K275, L276, A277, P278, W280, S281, I / M282, T / A / S283, L284, I285, N / S / T299.

[1108] In one embodiment, the present invention relates to the use or method as defined above, wherein the mutated extremely thermophilic phosphotriesterase further comprises at least one supplementary substitution, wherein the at least one supplementary substitution is selected from the group consisting of substitutions at positions Y99, Y101, R225 and C260 in SEQ ID NO:1.

[1109] In one embodiment, the present invention relates to the use or method as defined above, wherein the mutated extremely thermophilic PTE corresponds to the following sequence: SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107.

[1110] In one embodiment, the invention relates to the use or method as defined above, wherein said mutated hyperthermophilic PTE corresponds to the following sequence: SEQ ID NO:21, SEQ ID NO:65 or SEQ ID NO:109.

[1111] Furthermore, the present invention also relates to a composition comprising a mutated hyperthermophilic PTE having lactonase activity as defined above.

[1112] In a preferred embodiment, the composition as defined above comprising a mutated hyperthermophilic PTE having lactonase activity further comprises at least one detergent.

[1113] In a more preferred embodiment, the above composition can be used as a laundry detergent for cleaning materials impregnated with OP compounds, wherein the composition comprises a mutant extremely thermophilic PTE having lactonase activity and at least one detergent.

[1114] One aspect of the present invention relates to the use of the mutant hyperthermophilic PTE of the present invention for decontamination of organophosphorus compounds. This aspect is based on the ability of the mutant hyperthermophilic PTE to catalyze the hydrolysis of phosphoester bonds in OP.

[1115] Therefore, the present invention also relates to the use of a mutated hyperthermophilic PTE having lactonase activity as defined above, or a host cell as defined above, as a bioscavenger:

[1116] - in the context of decontamination of surfaces, skin or mucous membranes contaminated with organophosphorus compounds,

[1117] - in the context of the prevention or treatment of external or internal poisoning due to ingestion or inhalation of organophosphorus compounds,

[1118] - in the context of pollution control of water contaminated by organophosphorus compounds, or

[1119] - in the context of the destruction of a large number of neurotoxic agents.

[1120] In one embodiment, the present invention relates to the use as defined above, wherein the mutated extremely thermophilic PTE is selected from the group consisting of: SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:111, SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119.

[1121] In one embodiment, the present invention relates to the use as defined above, wherein the mutated extremely thermophilic PTE is selected from the group consisting of: SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:67, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:111, SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:21, SEQ ID NO:65 and SEQ ID NO:109.

[1122] Furthermore, a subject of the invention is a material impregnated with a mutated hyperthermophilic PTE having lactonase activity as defined above, said material being in liquid or solid form, for example gloves, various garments, wipes, spray foams.

[1123] Another subject of the invention is a kit for decontaminating materials, skin or mucosal surfaces contaminated with organophosphorus compounds, or for controlling the pollution of water contaminated with organophosphorus compounds, said kit comprising a mutant hyperthermophilic PTE having lactonase activity as defined above, or a material impregnated with a mutant hyperthermophilic PTE having lactonase activity as defined above.

[1124] Furthermore, a subject of the present invention is a bioscavenger of organophosphorus compounds comprising a mutated hyperthermophilic PTE having lactonase activity as defined above.

[1125] Furthermore, the present invention also relates to a cartridge for external decontamination, inside which a mutant hyperthermophilic PTE having lactonase activity as defined above is implanted. Said cartridge can be used for decontamination of the blood of an individual poisoned by OP compounds.

[1126] Another aspect of the present invention relates to the use of the mutant hyperthermophilic PTE of the present invention as an antibacterial agent. This aspect is based on the use of the mutant hyperthermophilic PTE of the present invention to hydrolyze lactones and thereby disrupt quorum sensing of microbial organisms that use homoserine lactone substrates for communication.

[1127] Therefore, the present invention relates to the use of a mutated extremely thermophilic phosphotriesterase as defined above for disrupting quorum sensing in bacteria.

[1128] In one embodiment, the present invention relates to the use of a mutated extremely thermophilic phosphotriesterase, wherein the mutated extremely thermophilic phosphotriesterase has a sequence corresponding to the consensus sequence of SEQ ID NO: 1, wherein the amino acid W at position 265 is substituted by an amino acid selected from isoleucine I, valine V, threonine T or alanine A, and the mutated extremely thermophilic phosphotriesterase has increased lactonase catalytic activity compared to the lactonase activity of the extremely thermophilic phosphotriesterase corresponding to the consensus sequence of SEQ ID NO: 1.

[1129] In one embodiment, the present invention relates to the use of a mutated extremely thermophilic phosphotriesterase as defined above for disrupting quorum sensing in bacteria, wherein the mutated extremely thermophilic PTE is selected from the group consisting of: SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107.

[1130] In one embodiment, the invention relates to the use of a mutated hyperthermophilic phosphotriesterase as defined above, wherein the mutated hyperthermophilic PTE is selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:65 and SEQ ID NO:109, for disrupting quorum sensing in bacteria.

[1131] In one embodiment, the present invention relates to the use of a mutated extremely thermophilic phosphotriesterase as defined above for disrupting quorum sensing in bacteria, wherein the mutated extremely thermophilic PTE is selected from the group consisting of: SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 23, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 67, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 111, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 21, SEQ ID NO: 65 and SEQ ID NO: 109.

[1132] In one embodiment, the present invention relates to the use of the mutated hyperthermophilic PTE of the present invention for limiting the formation of biofilms, in particular in ships or other marine equipment.

[1133] In particular, mutated hyperthermophilic PTEs may be added to the staining medium in order to limit the formation of biofilms, especially in ships or other marine equipment.

[1134] In one embodiment, the present invention relates to the use of the mutated hyperthermophilic PTE of the present invention for inhibiting fire blight in plants or for inhibiting rot in vegetables.

[1135] Fire blight of plants is caused by infection with bacteria of the genus Erwinia, while fire blight of vegetables is caused by infection with bacteria of the genus Serratia.

[1136] Colonization of plants and vegetables by Erwinia and Serratia bacteria involves quorum sensing based on lactone substrates. Such lactone substrates can be hydrolyzed by PTEs, thereby inhibiting and / or treating infections by Erwinia and Serratia.

[1137] A subject of the present invention is furthermore a phytosanitary composition comprising as active ingredient at least one mutated hyperthermophilic PTE as defined above.

[1138] A subject of the present invention is furthermore also an antibacterial composition comprising as active ingredient at least one mutated hyperthermophilic PTE as defined above.

[1139] Furthermore, the present invention also relates to a pharmaceutical composition comprising as an active ingredient at least one mutated hyperthermophilic PTE having lactonase activity as defined above, and a pharmaceutically acceptable vehicle.

[1140] Furthermore, the invention also relates to a pharmaceutical composition for the treatment of pathologies due to the presence of bacteria, in particular pneumonia or iatrogenic diseases.

[1141] In addition, the present invention also relates to a pharmaceutical composition for treating dental plaque.

[1142] Furthermore, the present invention also relates to a pharmaceutical composition for use as eye drops in the treatment of eye infections or healing of the eye surface.

[1143] In a preferred embodiment, the pharmaceutical composition as defined above further comprises at least one antibiotic selected from gentamicin, ciprofloxacin, ceftazidime, imipenem, toblamycin, wherein said pharmaceutical composition comprises a mutated extremely thermophilic PTE having lactonase activity.

[1144] In a more preferred embodiment, the pharmaceutical composition as defined above is in a form that can be administered by an injectable route, in particular in solution, packaged or pegylated, or in a form that can be administered by a topical route, in particular in the form of an ointment, spray or wipe.

[1145] Furthermore, the present invention also relates to the use of a material impregnated with or comprising a mutated extremely thermophilic PTE having lactonase activity as a bactericidal agent for decontamination of bacterial infections on surfaces.

[1146] Furthermore, the present invention also relates to a composition or a pharmaceutical composition for treating bacterial infections caused by bacteria that use homoserine lactone substrates for communication, wherein the composition or the pharmaceutical composition comprises a mutated extremely thermophilic PTE having lactonase activity, wherein the infections are particularly in blood, wounds, burns, skin, and biomaterial-body contact areas.

[1147] Furthermore, the subject of the present invention is a method for disrupting quorum sensing of microbial organisms that use homoserine lactone substrates for communication, which consists of administering to a patient in need thereof a sufficient amount of a composition or a pharmaceutical composition, wherein said composition or pharmaceutical composition comprises a mutated extremely thermophilic PTE having lactonase activity as defined above.

[1148] Furthermore, another subject of the present invention is also a mutated hyperthermophilic PTE as defined above for use as a medicament.

[1149] In one embodiment, the invention relates to a mutated hyperthermophilic PTE as defined above for use in treating a bacterial infection.

[1150] In one embodiment, the present invention relates to a mutated extremely thermophilic PTE as defined above for use in the treatment of pneumonia or nosocomial diseases, wherein the pneumonia or nosocomial diseases are caused by bacteria that use homoserine lactone substrates for communication, in particular in blood, wounds, burns, skin, biomaterial-body contact areas.

[1151] In one embodiment, the invention relates to a mutated hyperthermophilic PTE as defined above for use in treating dental plaque.

[1152] In one embodiment, the invention relates to a mutated hyperthermophilic PTE as defined above for use in the treatment of an eye infection or healing of the eye surface.

[1153] The present invention is further illustrated by the following figures and examples of the phosphotriesterase of Sulfolobus solfataricus and the phosphotriesterase of Sulfolobus solfataricus being mutated in the context of preparing a mutant hyperthermophilic PTE having lactonase activity as defined above according to the present invention. These examples are not intended to limit the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[1155] Figure 1 : Chemical structures of SsoPox substrates.

[1156] The figure shows the chemical structures of paraoxon (A.), CMP-coumarin (B.), 3-oxo-C12AHL (C.), 3-oxo-C10AHL (D.), undecane-δ-lactone (E.) and undecane-γ-lactone (F.).

[1157] Figure 2: Screening and characterization of SsoPox phosphotriesterase activity.

[1158] The relative phosphotriesterase activity of W263 saturation site variants was screened using 1 mM (A.) and 100 μM (B.) paraoxon substrates and 50 μM (C.) CMP-coumarin substrate. The best variants (i.e., SsoPoxW263F, W263M, W263A, and W263L) were characterized for paraoxon hydrolysis and the catalytic efficiency was compared to SsoPox wt (D.).

[1159] Figure 3: Screening and characterization of SsoPox lactonase activity.

[1160] Schematic diagram of the screening method based on lactonase activity of P. aeruginosa. The relative lactonase activity of W263 saturation site variants was screened for 3-oxo-C12 AHL hydrolysis (B.). The best variants (i.e., SsoPox W263I, W263V, W263T, and W263A) were characterized for 3-oxo-C12 AHL hydrolysis and the catalytic efficiency was compared to SsoPox wt (C.).

[1161] Figure 4 : SsoPox W263I-mediated inhibition of lasB transcription.

[1162] Graphs show expression in treated cultures as a percentage of lasB expression in untreated controls (no SsoPox W263I) and represent data averaged from 3 independent experiments, each with 3 technical replicates: Error bars represent 95% confidence intervals. Student's T-test for SsoPoxW263I, p=<0.05. All T-tests used compared baseline to highest dose of enzyme.

[1163] Figure 5 : Inhibition of PAO1 biofilm formation by SsoPoxW263I.

[1164] Biofilms were grown in MBEC devices as described in the Methods section. Inhibition of P. aeruginosa biofilm formation by SsoPox W263I was seen in a dose-dependent manner: Student's T-test for SsoPoxW263I, p=<0.05.

[1165] Figure 6 : Survival curves of the two groups of animals 48 hours after infection.

[1166] Animal infection has 10 8 CFU / mL (300 μL) of Pseudomonas aeruginosa PAO1 and untreated (NT) or immediately treated with SsoPoxW263I (IT).

[1167] Figure 7 : Histological examination of lungs after infection.

[1168] Pathological profiles of lungs representing untreated (NT) (A), differentially treated (DT) (B), and immediately treated (IT) (C) groups: Pathological Giemsa-stained x100 micrographs of lung sections. The mean histological severity score (HSS) was (mean ± SD) 2,64 ± 0.4 for the NT group, 1.27 ± 0.6 for the IT group (p = 0.005, vs. NT), and 2.32 ± 0.4 for the DT group (p = NS vs. NT). Example

[1169] Example 1

[1170] In this example, SsoPox variants were experimentally generated and characterized.

[1171] 1-Test process

[1172] 1.1- Initial Materials

[1173] The SsoPox coding gene was optimized for expression in Escherichia coli and synthesized by GeneArt (Life Technologies, France) [1]. The gene was then cloned into a customized version of pET32b (Novagen) (= pET32b-ΔTrx-SsoPox) with NcoI and NotI as cloning sites. The SsoPox sequence was verified by sequencage (Sequencage plateforme, Timone, Marseille, France). Both plasmids were used for the evolution protocol.

[1174] 1.2-Site-directed mutagenesis

[1175] The saturation site of position W263 of SsoPox was generated as required by the initially used plasmid pET22b-SsoPox, thus being provided as a provider (GeneArt, Invitrogen; Germany). Each variant was checked by sequencing and provided as a glycerol bank of E. coli DH5α cells. 20 plasmids (pET22b-SsoPox-W263X) were purified from E. coli DH5α cells and transformed into BL21 (DE3)-pLysS strain by electroporation for activity screening and into BL21 (DE3)-pGro7 / EL (TaKaRa) for mass production / purification (see relevant section below).

[1176] For other site-directed mutagenesis or saturation sites at selected positions, primers that introduce the desired changes were used to amplify the entire plasmid using pfu Turbo polymerase (Agilent). The PCR composition was completed according to the customer's instructions, with a final volume of 25 μL and amplified from 100 ng of plasmid. The PCR protocol was as follows:

[1177]

[1178] At 37 ° C for 45', the remaining initial plasmid was removed by DpnI enzyme digestion (1 μl; Fermentas). After inactivation at 90 ° C for 20', the DNA was purified (QIAquick PCR Purification Kit; Qiagen) to obtain about 30 μL variable amounts of DNA. Then, 5 μL of purified DNA was transformed into Escherichia coli electrocompetent cells (50 μL; E.cloni; Lucigen), recovered in 1 mL SOC medium at 37 ° C for 1 h, and then plated on agar medium supplemented with ampicillin (100 μg / mL). Multiple clones were sequenced to verify the well-implemented mutagenesis (Sequencageplateforme, Timone, Marseille, France), and the verified plasmid was transformed into Escherichia coli strain BL21 (DE3) -pGro7 / GroEL (TaKaRa) for mass production / purification and analysis (see relevant section below).

[1179] 1.3-Directed evolution method

[1180] use II Random Mutagenesis Kit, final 25 μL, using primers T7-promoter (TAA TAC GAC TCA CTA TAG GG) and T7-RP (GCT AGT TAT TGC TCA GCG G) and 500ng matrix (corresponding to 6μg pET32b-ΔTrx-SsoPox plasmid) to implement the directed evolution program. Other PCR elements were formed according to the customer's suggestions. The PCR protocol is as follows:

[1181]

[1182] The remaining plasmid was then digested by DpnI enzyme (1 μl; Fermentas) at 37°C for 45' and then inactivated at 90°C for 20'. Next, the DNA was purified (QIAquick PCR Purification Kit; Qiagen) to obtain approximately 50 μl of DNA at 100 ng / μl. For the next step, please refer to the "Cloning and library formation" section.

[1183] 1.4 - Methods

[1184] The SsoPox encoding gene was amplified by PCR (500 μL RedTaq; Sigma) from the pET32b-ΔTrx-SsoPox plasmid using primers T7-Promoter (TAA TAC GAC TCA CTA TAG GG) and T7-RP (GCT AGT TAT TGCTCA GCG G). The PCR protocol was as follows:

[1185]

[1186] The remaining plasmid was then digested by DpnI enzyme (1 μl; Fermentas) at 37° C. for 45′ and then inactivated at 90° C. for 20′. Next, the DNA was purified (QIAquick PCR Purification Kit; Qiagen) to obtain approximately 100 μl of DNA at 200 ng / μl. 15 μL DNA (~3 μg) was digested by 2UE of DNAseI (TaKaRa) in buffer TrisHCl 100mM pH 7.5, MnCl2 10mM at 20°C during 30", 1' and 2'. The digestion was terminated by incubation at 90°C for 10' in the presence of 60mM EDTA. After centrifugation, DNA aliquots were combined and subjected to agarose gel electrophoresis in TAE buffer (2%; w / v) at 50mA for 15'. Fragments consisting of an average size of 70 bp (ranging from 50 to 150 pb) were excised from the gel and quantified using a D-tube TM Purification was performed using a Dyalizer Maxi (Calbiochem) apparatus.

[1187] DNA extracted from gel (concentration> 12ng / μL) was used as substrate in "assembly PCR" consisting of 100ng substrate, 2pmol primers with introduced mutations and 2.5UE of Pfu Turbo polymerase (Agilent) in a final volume of 25μl. The primer mixture consisted of an oligonucleotide mixture consisting of equal amounts of modified positions. The PCR protocol was as follows:

[1188]

[1189] In the direction 5'-3', the primers that introduced mutations were as follows:

[1190] SEQ ID NO Primer Sequence 5′-3′ SEQ ID NO:268 W263M-F TGCACCATTGATATGGGCACCGCA AAACCG SEQ ID NO:269 W263M-R CGGTTTTGCGGTGCCCATATCAATGGTGCA SEQ ID NO:270 W263L-F TGCACCATTGATCTGGGCACCGCAAAACCG SEQ ID NO:271 W263L-R CGGTTTTGCGGTGCCCAGATCAATGGTGCA SEQ ID NO:272 W263A-F TGCACCATTGATGCAGGCACCGCAAAACCG SEQ ID NO:273 W263A-R CGGTTTTGCGGTGCCTGCATCAATGGTGCA SEQ ID NO:274 W263I-F TGCACCATTGATATTGGCACCGCAAAACCG SEQ ID NO:275 W263I-R CGGTTTTGCGGTGCCAATATCAATGGTGCA SEQ ID NO:276 W263V-F TGCACCATTGATGTTGGCACCGCAAAACCG SEQ ID NO:277 W263V-R CGGTTTTGCGGTGCCAACATCAATGGTGCA SEQ ID NO:278 W263T-F TGCACCATTGATACCGGCACCGCAAAACCG SEQ ID NO:279 W263T-R CGGTTTTGCGGTGCCGGTATCAATGGTGCA SEQ ID NO:280 C258L-F ATTAGCCATGATTATCTGTGCACCATTGAT SEQ ID NO:281 C258L-R ATCAATGGTGCACAGATAATCATGGCTAAT SEQ ID NO:282 I261F-F GATTATTGCTGCACCTTTGATTGGGGCACC SEQ ID NO:283 I261F-R GGTGCCCCAATCAAAGGTGCAGCAATAATC SEQ ID NO:284 V27A-F GAACATCTGCGTGCATTTAGCGAAGCAGTT SEQ ID NO:285 V27A-R AACTGCTTCGCTAAATGCACGCAGATGTTC SEQ ID NO:286 Y97W-F GGCACCGGTATTTGGATTTATATCGATCTGCCG SEQ ID NO:287 Y97W-R CGGCAGATCGATATAAATCCAAATACCGGTGCC SEQ ID NO:288 L228M-F GATCGTTATGGTCTGGACATGTTTCTGCCGGTT SEQ ID NO:289 L228M-R AACCGGCAGAAACATGTCCAGACCATAACGATC SEQ ID NO:290 I280T-F GCACCGCGTTGGAGCACTACCCTGATTTTTG SEQ ID NO:291 I280T-R CAAAAATCAGGGTAGTGCTCCAACGCGGTGC SEQ ID NO:292 F46L-F CTGTATAATGAAGATGAAGAACTGCGCAATGCCGTGAATGAAG SEQ ID NO:293 F46L-R CTTCATTCACGGCATTGCGCAGTTCTTCATCTTCATTATACAG SEQ ID NO:294 I76T-F GTTATGGGTCTGGGTCGTGATACTCGTTTTATGGAAAAAGTTGTG SEQ ID NO:295 I76T-R CACAACTTTTTCCATAAAACGAGTATCACGACCCAGACCCATAAC SEQ ID NO:296 Y99F-F GGCACCGGTATTTATATTTTTATCGATCTGCCG SEQ ID NO:297 Y99F-R CGGCAGATCGATAAAAATATAAATACCGGTGCC SEQ ID NO:298 L130P-F GGCATTCAGGGCACCCCGAATAAAGCAGGTTTTG SEQ ID NO:299 L130P-R CAAAACCTGCTTTATTCGGGGTGCCCTGAATGCC SEQ ID NO:300 L226V-F GATCGTTATGGTGTGGACCTGTTTCTGCCGGTT SEQ ID NO:301 L226V-R AACCGGCAGAAACAGGTCCACACCATAACGATC SEQ ID NO:302 L72I-F GTTATGGGTATTGGTCGTGATATTCGTTTT

[1191] SEQ ID NO Primer Sequence 5′-3′ SEQ ID NO:303 L72I-R AAAACGAATATCACGACCAATACCCATAAC SEQ ID NO:304 F229S-F GATCGTTATGGTCTGGACCTGTCTCTGCCGGTT SEQ ID NO:305 F229S-R AACCGGCAGAGACAGGTCCAGACCATAACGATC SEQ ID NO:306 T68S-F AAAACCATTGTTGATCCGAGTGTTATGGGT SEQ ID NO:307 T68S-R ACCCATAACACTCGGATCAACAATGGTTTT SEQ ID NO:308 K8E-F CATTCCGCTGGTTGGTGAAGATAGCATTGAAAG SEQ ID NO:309 K8E-R CTTTCAATGCTATCTTCACCAACCAGCGGAATG SEQ ID NO:310 P67S-F AAAACCATTGTTGATTCGACCGTTATGGGT SEQ ID NO:311 P67S-R ACCCATAACGGTCGAATCAACAATGGGTTTT SEQ ID NO:312 K164N-F CAATAAAGAAACCAAGTGTTCCGATTATTACCC SEQ ID NO:313 K164N-R GGGTAATAATCGGAACATTGGTTTCTTTTATTG

[1192] Table 1: List of primers used to create SsoPox variants

[1193] Finally, assembly PCR was used as a matrix for "nested PCR". 1 μL assembly PCR was used as a conventional PCR (50 μL, RedTaq; Sigma), and the cloning primers were SsoPox-lib-pET-5' (ATGCGCATTCCGCTGGTTGG) and SsoPox-lib-pET-3' (TTATTAGCTAAAGAATTTTTTCGGATTTTC). The PCR protocol was as follows:

[1194]

[1195] 1.5- Cloning and library formation

[1196] The PCR product was purified using an extraction kit (QIAquick PCR Purification Kit; Qiagen) and then digested by NcoI Fastdigest and NotI Fastdigest enzymes (12UE each; Fermentas) at 37°C for 45'. The enzymes were then inactivated by 20' incubation at 90°C and then purified (QIAquick PCR Purification Kit; Qiagen) in order to be cloned into the previously dephosphorylated corresponding restriction sites of the pET32b-Δtrx plasmid (10UE / μl CIP; NEB) according to the customer's advice. Ligation (20UE; NEB) was performed using 50ng of plasmid and T4-DNA ligase (molar ratio of 1:3) at 16°C for 16h.

[1197] After ligation, the ligase was inactivated at 90°C for 20', then purified from the salt form by conventional alcohol precipitation and recovered in 10 μL of water. 5 μL of the purified ligation was used to electroporate E. coli electrocompetent cells (50 μL; E.cloni; Lucingen) and recovered in 1 mL of SOC medium at 37°C within 1 h. Then, 1 mL of the entire material was plated on agar selection medium (ampicillin 100 μg / mL) and incubated overnight at 37°C.

[1198] On the agar plate, more than 10 4 After the transformation efficiency of the colonies, 1 mL of plasmid extraction kit solution 1 (Qiaprep Spin Miniprep kit; Quiagen) was used to harvest the colonies, and then the plasmids were extracted from the cells according to the recommended procedure. The obtained plasmid pool constituted the library, and 100 ng was used for electroporation of 50 μL electrocompetent BL21 (DE3) -pGro7 / EL (TaKaRa). After recovery in SOC medium at 37 ° C for 1 h, the cells were plated on agar plates with ampicillin (100 μg / mL) and chloramphenicol (37 μg / mL).

[1199] 2- Screening process

[1200] Microcultures consisting of 600 μL ZYP medium [3,4] supplemented with ampicillin (100 μg / mL) and chloramphenicol (34 μg / mL) were inoculated into 96-well plates by picking colonies with a pipette tip. After the culture was grown for 5 h at 37°C with shaking at 1600 rpm, activation was mediated by transitioning the temperature to 25°C and adding CoCl2 (0.2 mM) and arabinose (0.2%, w / v). After overnight growth, the pipette tip was removed and used to pick separate colonies on agar plates (ampicillin 100 μg / mL; chloramphenicol 34 μg / mL) for strain preservation. The culture was centrifuged to retain the cell pellet, which was resuspended in a lysis buffer consisting of 50 mM HEPES pH 8, 150 mM NaCl, CoCl2 0.2 mM, Lysozyme 0.25 mg / ml, PMSF 0.1 mM DNAseI 10 μg / ml and MgSO4 20 mM. The cells were disrupted by a freeze / thaw step and the cell debris was removed by centrifugation (13 000 g, 4 ° C, 30'). Partial purification of the protein was performed and the ultra-high thermal stability of SsoPox was explored by incubation at 70 ° C for 15 minutes [5]. Aggregated protein was harvested by centrifugation (13 000 g, 25 ° C, 30').

[1201] 2.1-Screening of phosphotriesterase activity

[1202] Screening for phosphotriesterase activity was mediated by monitoring the hydrolysis of chromophore phosphotriesters (paraoxon, methyl-paraoxon, parathion, methylparathion (1 mM or 100 μM, Fluka)). Kinetic assays were performed in 96-well plates at 25°C in a 6.2 mm path length cell for 200 μL reactions using a microplate reader (Synergy HT; BioTek, USA) and Gen5.1 software for 10' monitoring of phosphotriesters (ε 405nm =17 000M -1 cm -1 ). Standard assays were performed in pte buffer (50 mM HEPES pH 8, 150 mM NaCl, 0.2 mM CoCl2).

[1203] 2.2-Screening of lactonase activity

[1204] Screening for lactonase activity was mediated by a genetically modified strain of Pseudomonas aeruginosa, PAO1 (PAO1-ΔlasI-JP2). In Pseudomonas aeruginosa, the JP2 plasmid encodes a protein that encodes a bioluminescent product in the presence of 3-oxo-C12AHL; the lasI gene responsible for 3-oxo-C12AHL synthesis in wt P. aeruginosa was deleted. SsoPox variants (5 μL of a 10-fold dilution of partially purified variants) were mixed with 3-oxo-C12AHL (100 nM) in 100 μL pte buffer and incubated at room temperature for 20 minutes. A volume of 450 μL of LB medium (trimethoprim lactate at 300 μg / mL) was inoculated with an overnight preculture of Pseudomonas aeruginosa PAO1-ΔlasI-JP2 (1 / 50) and supplemented with the protein / AHL mixture (50 μL). The final theoretical concentration of 3-oxo-C12AHL was 20 mM before enzymatic hydrolysis of SsoPox. After 270 min of incubation at 37°C, the cell density (OD) of 200 μL culture aliquots was measured in 96-well plates using a microplate reader (Synergy HT, BioTek, USA) monitored by Gen5.1 software. 600nm ) and bioluminescence (460-40 nm; intensity 100). Controls consisted of the same experiments but without enzyme and / or without AHL.

[1205] The best variants were re-plated and then placed in microculture as described previously, and each clone was presented 4 times. The previous protocol was implemented exactly the same, thereby demonstrating the results described. However, the lysis buffer and the pte buffer did not contain CoCl2 salts, thereby avoiding the loss of enzyme affinity for metals in the improved method.

[1206] 3- Improved proof and analysis

[1207] The best variants are then sequenced (Sequencage plateforme, Timone, Marseille, France) and produced in large quantities for analysis of catalytic properties. The genes or plasmids selected for the best improvement can be used to implement the next round of diversity formation (ie, return to the first part).

[1208] Large quantities of protein were produced using the Escherichia coli strain BL21(DE3)-pGro7 / GroEL (TaKaRa). Production was performed in 500 mL ZYP medium [3] (100 μg / ml ampicillin, 34 μg / ml chloramphenicol) as previously described [4, 6, 7], with the addition of 0.2% (w / v) arabinose (Sigma-Aldrich; France) to induce expression of the chaperone protein GroEL / ES and a temperature transition to 25°C. Purification was performed as previously described [7]. Briefly, a single step of incubation at 70°C for 30' was performed, followed by differential ammonium sulfate precipitation, dialysis and size exclusion chromatography. Proteins were quantified using an ultramicrospectrophotometer (nanodrop, thermofisher scientific, France) using the protein molar extinction coefficient generated from the protein primary sequence in PROT-PARAM (Expasy tool software) [8]. 3.1- Kinetic commonalities

[1209] Catalytic parameters were evaluated at 25 °C and recorded in 96-well plates in a 6.2 mm path length cell for 200 μL of reaction using a microplate reader (Synergy HT, BioTek, USA) and Gen5.1 software as previously described [6]. Catalytic parameters were obtained by fitting the data to the Michaelis-Menten (MM) equation [9] using Graph-Pad Prism 5 software. When V could not be reached in the experiment, max The catalytic efficiency was obtained by fitting the linear part of the MM plot to a linear regression using Graph-Pad Prism 5 software.

[1210] 3.2-Characterization of phosphotriesterase activity

[1211] The PNP derivatives of OP (ε 405nm =17 000M -1 cm -1 ), neurological agent coumarin derivatives (CMP-coumarin, IMP-coumarin, PinP-coumarin)

[10] (ε 412nm =37 000M -1 cm -1 ) or Malathion (ε 412nm =13 700M -1 cm -1 ). In addition, kinetics were performed in PTE buffer supplemented with 0.1 ...

Claims

1. Use of a single mutation that increases the lactonase catalytic activity of an extremely thermophilic phosphotriesterase, wherein the extremely thermophilic phosphotriesterase has a sequence corresponding to the consensus sequence of SEQ ID NO: 1, wherein the amino acid W at position 265 is substituted with an amino acid selected from the group consisting of isoleucine I, valine V, threonine T or alanine A, thereby obtaining a mutant extremely thermophilic phosphotriesterase having an increased lactonase catalytic activity compared to the lactonase activity of the extremely thermophilic phosphotriesterase corresponding to the consensus sequence shown in SEQ ID NO: 1, The mutations are not used for the purpose of treating diseases.

2. The use according to claim 1, wherein the extremely thermophilic phosphotriesterase is a wild-type extremely thermophilic phosphotriesterase.

3. The use according to claim 1, wherein the hydrolysis of 3-oxo-C12 AHL by the mutant extremely thermophilic phosphotriesterase is increased by at least 2 times compared to the hydrolysis of 3-oxo-C12 AHL by the extremely thermophilic phosphotriesterase.

4. The use according to claim 3, wherein the hydrolysis of 3-oxo-C12 AHL by the mutant extremely thermophilic phosphotriesterase is increased by 2 to 70 times compared to the hydrolysis of 3-oxo-C12 AHL by the extremely thermophilic phosphotriesterase.

5. The use according to claim 3, wherein the mutated extreme thermophilic phosphotriesterase increases the hydrolysis of 3-oxo-C12 AHL by 40 to 50 times compared to the hydrolysis of 3-oxo-C12 AHL by the extreme thermophilic phosphotriesterase.

6. The use according to claim 1, wherein the mutated extremely thermophilic phosphotriesterase is thermostable.

7. purposes according to claim 1, wherein the amino acid at position 2 is deleted in SEQ ID NO:

1.

8. The use according to claim 1, wherein the extremely thermophilic phosphotriesterase is selected from: SEQ ID NO: 3 obtained from Sulfolobus solfataricus; SEQ ID NO: 5 obtained from Sulfolobus acidocalaricus; and SEQ ID NO: 7 obtained from Sulfolobus islandicus, wherein the sequences SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7 belong to the common SEQ ID NO: 1, SEQ ID NO: 5 lacks the amino acid at position 2 in SEQ ID NO: 1, and SEQ ID NO: 3 and SEQ ID NO: 7 lack the amino acids at positions 2 and 3 in SEQ ID NO:

1.

9. The method according to claim 1, wherein the amino acid W at position 265 is substituted by the amino acid isoleucine I.

10. The use according to claim 1, wherein the mutant extremely thermophilic phosphotriesterase is selected from the group consisting of: SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105 and SEQ ID NO:

107.

11. A mutant extremely thermophilic phosphotriesterase, whose amino acid sequence is selected from: SEQ ID NO: 21, SEQ ID NO: 65 and SEQ ID NO:

109.

12. Use of a mutated extremely thermophilic phosphotriesterase as defined in any one of claims 1 to 11 for disrupting quorum sensing in bacteria in vitro.

13. Use of the mutant extremely thermophilic phosphotriesterase according to claim 12 for limiting the formation of biofilms in ships or other marine equipment.

14. Use of the mutant extremely thermophilic phosphotriesterase according to claim 12 for inhibiting fire blight of plants or inhibiting rot of vegetables.

15. A phytosanitary composition comprising as an active ingredient at least one mutated extremely thermophilic phosphotriesterase as defined in any one of claims 1 to 11.

16. An antibacterial composition comprising as an active ingredient at least one mutated extremely thermophilic phosphotriesterase as defined in any one of claims 1 to 11.

17. A pharmaceutical composition for treating bacterial infections caused by bacteria that use homoserine lactone substrates for communication, comprising as an active ingredient at least one mutated extremely thermophilic phosphotriesterase as defined in any one of claims 1 to 11, in combination with a pharmaceutically acceptable vehicle.

18. A composition according to any one of claims 15 to 17, comprising as an active ingredient at least one mutated extremely thermophilic phosphotriesterase as defined in any one of claims 1 to 11, in combination with a pharmaceutically acceptable vehicle.

19. The composition according to claim 18, further comprising at least one antibiotic selected from the group consisting of gentamicin, ciprofloxacin, ceftazidime, imipenem and tobramycin.

20. A mutant extremely thermophilic phosphotriesterase having lactonase activity and derived from an extremely thermophilic phosphotriesterase defined by the consensus sequence SEQ ID NO: 1, wherein the mutant extremely thermophilic phosphotriesterase has a single mutation, wherein the tryptophan W at position 265 of the consensus sequence SEQ ID NO: 1 is replaced by an amino acid selected from the group consisting of isoleucine I, valine V, threonine T or alanine A.

21. The mutant extremely thermophilic phosphotriesterase according to claim 20, wherein the mutant extremely thermophilic phosphotriesterase has a single mutation, wherein the tryptophan W at position 265 of the consensus sequence SEQ ID NO: 1 is replaced by threonine T.

22. A mutant extremely thermophilic phosphotriesterase having a lactonase activity derived from an extremely thermophilic phosphotriesterase defined by the sequence SEQ ID NO: 3, wherein the mutant extremely thermophilic phosphotriesterase has a single mutation, wherein the tryptophan W at position 263 of the sequence SEQ ID NO: 3 is replaced by isoleucine I, valine V, threonine T or alanine A.

23. Use of a phosphotriesterase as defined in any one of claims 1 to 11 for the preparation of a medicament for the treatment of bacterial infections caused by bacteria that use homoserine lactone substrates for communication.

24. The use according to claim 23, wherein the bacterial infection is pneumonia or nosocomial disease.

25. The use according to claim 24, wherein the bacterial infection is caused by bacteria that use homoserine lactone substrates for communication in the blood, wounds, burns, skin or biomaterial-body contact areas.

26. Use of a phosphotriesterase as defined in any one of claims 1 to 11 in the preparation of a medicament for treating dental plaque.

27. Use of a phosphotriesterase as defined in any one of claims 1 to 11 in the preparation of a medicament for treating eye infections.